[CONTACT_23015]â€™s /Journey Medical Page 1 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 1 TITLE PAGE 
 
Title: A Multicenter, Randomized, D ouble-Blind, Parallel-Group, 
Active and Placebo -Controlled Study to Assess the Safety, 
Efficacy, and Tolerability of Oral DFD -29 Extended Release 
Capsules for the Treatment of Inflammatory Lesions of Rosacea 
Over 16 Weeks 
 
Protocol No.: DFD-29-CD-004 
Acronym:  MVOR-1 
Co-Sponsors: [CONTACT_23015]â€™s Laboratories Ltd.,  
8-2-337, Road No. 3 
Banjara Hills, Hyderabad  
Telangana 500034, India  
Phone: +[ADDRESS_122437]., Suite 105    
Scottsdale, AZ [ZIP_CODE] , [LOCATION_003] 
Phone: +[PHONE_2521] 
  
Phase: 3 
Protocol Version: 2.0  
Amendment No:  01 
Current Protocol Version 
Date:    23 June 2022 
Previous Version of the    
Protocol:  Version 1.[ADDRESS_122438]. Reddyâ€™s Laboratories Ltd.  and Journey Medical Corporation. Nothing herein is to be 
reproduced, published or disclosed to others, in any form, without the prior express written consent 
of [CONTACT_23015]â€™s Laboratories Ltd.  and/or Journey Medical Corporation. Persons to whom this, or 
any information related to the contents  of this document, is to be disclosed must be informed that 
the information is privileged and confidential and must not be further disclosed by [CONTACT_476]. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 2 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 2 SPONSOR/CRO SIGNATURE [CONTACT_110225]:  DFD-29-CD-004 
PROTOCOL VERSION:  2.0  
AMENDMENT NO.:  01 
PROTOCOL DATE:  23 June 2022   
PROTOCOL TITLE:  A Multicenter, Randomized, Double-Blind, Parallel-Group, 
Active and Placebo-Controlle d Study to Assess the Safety, 
Efficacy, and Tolerability of Oral DFD-[ADDRESS_122439]. ReddyÂ´s Laboratories Ltd. 
      
Srinivas Sidgiddi, M.D.                                                                               Date 
Vice President Clinical Development & Medical Affairs Journey Medical Corporation 
   
 
      
Debra A. Dow, PharmD  Date 
Vice President, Scientific Affairs  Symbio, LLC  

	
		


	

Debra DowDigitally signed by [CONTACT_110168]: 2022.07.25 10:38:25 -07'00'
[CONTACT_23015]â€™s /Journey Medical Page 3 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 3 SYNOPSIS AND STUDY FLOW CHART 
3.1 Synopsis 
Title of Study: A Multicenter, Randomized, Double-B lind, Parallel-Group, Active and 
Placebo Controlled Study to Assess the Safet y, Efficacy and Tolerability of Oral DFD -29 
Extended Release  Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 
16 Weeks 
Name [CONTACT_790]: [CONTACT_23015]â€™s Laboratories Ltd., India  
Name [CONTACT_2756]: DFD-29 Extended Release Capsules  
Name [CONTACT_3261]: Minocycline HCl 
Objectives 
Primary : To evaluate the safety, efficacy, and tolerability of oral DFD-29 (Minocycline HCl 
Extended Release Capsules) , 40 mg (hereafter referred to as DFD- 29) compared to placebo in 
the treatment of papulopustular rosacea for 16 weeks 
Secondary : To evaluate the safety, efficacy, and tolerability of DFD- 29 compared to  
Doxycycline capsules 40 mg ( an authorized generic of OraceaÂ® in the [LOCATION_002])  in the 
treatment of papulopustular  rosacea for 16 weeks  
Study Design: This is a 16-week, multicenter, ra ndomized, parallel-group, double-blind, 
controlled study. After assessi ng eligibility during a screening period of up to [ADDRESS_122440] 18 years ol d who are diagnosed with moderate to severe 
papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), D oxycycline 
capsules  [ADDRESS_122441] visits are scheduled at Screening, Ba seline (Day 1), and Weeks 2, 4, 8, 12, and 16. 
Clinical assessments of  efficacy will be conducted based on Investigatorâ€™s Global Assessment 
modified scale without erythema (IGA), Clin icianâ€™s Erythema Assessme nt (CEA), and total 
inflammatory lesion count at Weeks 2, 4, 8, 12, and 16 compared to Baseline.  
Laboratory assessments of blood (hematology and biochemistry) and urine (routine tests) will 
be conducted at Screening and Week 16 (end of st udy [EOS] or early termination) to assess for 
any changes in the safety para meters. Other safety assessments  include vital signs, physical 
examination, urine pregnancy tests (for females of childbearing potential), and collection of AE 
data.  
The impact of the treatment on the quality of life  (QoL) of the subjects will be assessed using 
the rosacea -specific tool RosaQoL in addition to the Dermatology Life Quality Index (DLQI) at 
Baseline and Weeks 2, 4, 8, 12, and 16.  
Number of Study Centers: Approximately 29 study centers in the [LOCATION_002] (US) to enroll 
a total of approximately 320 subjects.  
Duration of Participation: Each subject will participate in the study for approximately 
[ADDRESS_122442] signs the informed consent f orm (ICF) through the final 
contact. The screening period is up to 30 days and duration of treatment  is 16 weeks. 
Duration of Study: The study will require approximately 10 months from the beginning to the 
end of the study (first subject signing the ICF to last contact [CONTACT_110169]). 		


	
[CONTACT_23015]â€™s /Journey Medical Page 4 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 Key Inclusion/Exclusion Criteria:  Male and female subjects at least 18 years of age in good 
general he alth with a clinical diagnosis of papulopustular rosacea, IGA grade 3 (moderate) or 
grade 4 (severe)  at Baseline will be selected  to participate in the study. Subjects must have 15 
to 60 (both inclusive) inflammatory lesions (papul es and pustules) of rosacea over the face and 
not more than [ADDRESS_122443], Dose, Route of Administration, and Regimen: 
To maintain the double -blind design, all 3 study medications will be over- encapsulated with the 
original capsules enclosed within a second, larger  (size 0) capsule shell. 
Investigational product : DFD-29 (Minocycline Hydroc hloride Extended Release Capsules), 
40 mg ([CONTACT_23015]â€™s Laboratories, Ltd. ) 
Active control : Doxycycline Capsules 40 mg [ an authorized generic of OraceaÂ® in the United 
States  (marketed by [CONTACT_110170], Mason OH [ZIP_CODE] [LOCATION_003])] 
Placebo : Capsules matching DFD- 29 with same excipi[INVESTIGATOR_110135] ([CONTACT_110229]â€™s Laboratories Ltd.)  
The study medication will be taken at a fixe d time of the day once a day for [ADDRESS_122444].  
Statistical Methods:   
Analysis Populations:  
x Intent-to-treat (ITT) population includes all randomized subjects (i.e., assigned to a 
treatment group). The ITT population will be the pr imary population for the efficacy 
analysis. 
x Safety population includes subjects who receive d at least one dose of study medication 
and had at least one safety assessment post- Baseline. The safety population will be used 
for analysis of tolerability and safety variables.  
x Per-protocol population (PP) comprises all subjects who did not violate the protocol in 
a way that might affect the evaluati on of the effect of the study medic ation on the primary 
endpoint (without major protocol violations or deviations). Key protocol deviation 
categories that would influence the decision to include  a subject in the PP population at 
time of final review before study  database lock will be pre- specified in the Statistical 
Analysis Plan (SAP).   
Sample Size:  The sample size was calculated based on  results of a Phase 2 study with orally 
administered DFD -29 (40 mg) in the treatment of i nflammatory lesions of papulopustular 
rosacea.  Based on the sample size ca lculations and an assumed dropout rate of 20%, the final 
planned sample size is [ADDRESS_122445] both placebo and D oxycycline 
capsules 40 mg in terms of efficacy on both co-primary endpoints. 
  		


	
[CONTACT_23015]â€™s /Journey Medical Page 5 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 Safety/Tolerability Endpoints: 
The following parameters have been defined as  endpoints regarding safety and tolerability: 
x Change from Baseline to each scheduled time point up to End of Study (EOS) for vital 
signs, physical examination and clinical laboratory tests. The clinical laboratory tests 
obtained at screening visit will be defined as baseline assessments.   
x Treatment-emergent AEs up to EOS. 
x Treatment-emergent AEs leading to pre mature discontinuation of study drug. 
x Treatment-emergent SAEs up to EOS.  
For pre -existing conditions, any event that worsens during treatment will be considered 
treatment emergent.  
Efficacy Endpoints: 
Co-Primary Efficacy Endpoints: 
 
x Proportion of subjects with IGA (modified scal e without erythema) â€˜treatment successâ€™ 
â€“ Grade [ADDRESS_122446] 2 grade re duction from Baseline to Week 16, in 
the DFD-29 group compared to Placebo  
x Total inflammatory lesion count (sum of papule s, pustules, and nodules) reduction from 
Baseline to Week 16, in the DFD-29 group compared to Placebo  
Secondary Efficacy Endpoints:  
x Percentage Change in Total inflammatory lesion count (sum of papules, pustules, and 
nodules) from Baseline to Week 16, in the DFD-[ADDRESS_122447] 2- grade reduction in CEA score from Baseline to 
Week 16 in the DFD-29 group compared to Placebo. 
x Change in DLQI score from Ba seline to Week 16 in the DFD- 29 group compared to 
Placebo. 
Exploratory Efficacy Endpoints:  
All the following endpoints for DFD -[ADDRESS_122448] Placebo and D oxycycline 
capsules  40 mg 
x Proportion of subjects with I GA â€˜treatment successâ€™  from Baseline to Weeks 2, 4, 8 and 
12. 
x Total inflammatory lesion count (sum of pa pules, pustules, and nodules) reduction from 
Baseline to Weeks 2, 4, 8 and 12. 
x Percentage Change in Total i nflammatory lesion count (sum of papules, pustules, and 
nodules) from Baseline to Weeks 2, 4, 8, 12 (and 16, in case of DFD-29 vs D oxycycline 
capsules 40 mg comparison).  
x Proportion of subjects with at least 2- grade reduction in IGA score from Baseline to 
Weeks 2, 4, 8 12 and 16. 
x Change in RosaQoL score from Ba seline to Weeks 2, 4, 8, 12 and 16. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 6 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 x Change in DLQI score from Baseline to Weeks 2, 4, 8, 12 (and 16, in case of DFD-29 
vs Doxycycline capsules 40 mg comparison). 
x Proportion of subjects with at least  2-grade improvement in the CEA score at Weeks 2, 
4, 8, 12 (and 16, in case of DFD-29 vs Doxycycline capsules 40 mg comparison).  
Safety and Tolerability Analysis  
Safety and tolerability data w ill be listed individually and summarized using descriptive 
statistics and frequency tables.  
Efficacy Analysis 
Co-Primary Endpoints: 
x The proportion of subjects with IGA treatment success (DFD- 29 versus placebo) will be 
investigated with a Cochran-Mantel-Haenszel (CMH) test f or general association 
adjusted for site. Treatment success is defined as having at least a 2- grade reduction from 
Baseline with Grade 0 or 1 at Week 16. 
x The difference between the treatments (DFD- 29 versus placebo) in terms of the change 
from Baseline in the total inflammatory lesi on count at Week 16 will be tested using an 
Analysis of Covariance (ANCOVA) model with treatment and site included in the model 
as fixed effects, and Baseline total i nflammatory lesion count as a covariate. 
Secondary Endpoints : 
x Percentage Change in Total inflamma tory lesion count (sum of papules, pustu les, and 
nodules) from Baseline to Week 16, in the DFD-29 group compared to Placeb o will be 
tested using an ANCOVA model with treatment and site included as fixed effects, and 
Baseline total inflammatory les ion count as a covariate. 
x Proportion of subjects with IGA treat ment success (DFD-29 versus D oxycycline 
capsules 40 mg) at Week [ADDRESS_122449] f or general association 
adjusted for site.  
x The difference between treatments (DFD -29 versus Doxycycli ne capsules 40 mg ) in 
change from Baseline in th e total inflammatory lesion count at Week [ADDRESS_122450] f or general association adjusted for site 
(DFD-29 versus placebo).  
x Change in DLQI score from Baseline to Week 16 will be investigated using an 
ANCOVA model with treatment and site in cluded as fixed effects, and Baseline DLQI 
score as a covariate (DFD-29 versus placebo). 
 		


	
[CONTACT_23015]â€™s /Journey Medical Page 7 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 Exploratory Endpoints: 
All the following endpoints for DFD -[ADDRESS_122451] a 2- grade reduction from Baseline with 
Grade 0 or 1. 
x The difference between treatments in terms of the change from Ba seline in the total 
inflammatory lesion count at Weeks 2, 4, 8 and 12 will be tested using mixed model 
repeated measures (MMRM) with trea tment, site, visit, and treatment-by- visit 
interaction included in the model as fixed effect s, Baseline total inflammatory lesion 
count as a covariate, and the subjects as a random factor 
x Percentage Change in Total inflammatory lesion count (sum of papules, pustules, and 
nodules) from Baseline to Weeks 2, 4, 8, 12 (and 16, in case of DFD-29 vs D oxycycline 
capsules 40 mg comparison) will be tested using MMRM with treatment, site, visit, and 
treatment-by- visit interaction included in the mode l as fixed effects, Baseline total 
inflammatory lesion count as a covariate, and the subjects as a random factor 
x The proportion of subjects with at least 2- grade reduction in IGA score from Baseline to 
Weeks 2, 4, 8, [ADDRESS_122452] f or general association 
adjusted for site. 
x Change in total RosaQoL score from Baseline to Weeks 2, 4, 8, 12 and 16 will be 
investigated using MMRM with treatm ent, site, visit, and treatment-by- visit interaction 
included in the model as fixed effects, Baseline RosaQoL as a covariate, and the subjects 
as a random factor. 
x Change in DLQI score from  Baseline to Weeks 2, 4, 8, 12 (and 16, in case of DFD -29 
vs Doxycycline capsules 40 mg compar ison) will be investigated using MMRM with 
treatment, site, visit, and treatment-by- visit interaction included in the model as fixed 
effects, Baseline DLQI as  a covariate, and the subjects as a random factor. 
x Proportion of subjects with at least a 2-grade improvement in the CEA score from 
Baseline to Weeks 2, 4, 8, 12 (and 16, in case of DFD-29 vs Doxycycline capsules 40 
mg comparison) will be investigated with a CMH test f or general association adjusted 
for site. 
Exploratory analyses for the following subgroups will be performed with respect to the primary 
endpoints:  
x Males versus females. 
x Baseline Moderate (IGA 3) versus severe (IGA 4). 
x Baseline Inflammatory lesion count below versus above Median count. 
x Fitzpatrick skin types I-III versus IV-VI  
 
 
Interim Analysis: No formal interim analysis is planned.  		


	
[CONTACT_23015]â€™s /Journey Medical Page 8 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 3.2 Study Flow Chart 
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6  Visit 7 
Screening Baseline Week 2  Week 4 Week 8 Week 12 Week 16  EOS/ET 
Study Day  Day -30 to 
Day -3 Day 1 Day 14 
(Â± 3 days) Day 29 
(Â± 3 days) Day 57 
(Â± 5 days) Day 85 
(Â± 5 days) Day 113  
(Â± 5 days) 
Informed Consent X       
Demographic Data including 
Fitzpatrick Skin Type X       
Inclusion and Exclusion Criteria X X      
Eligibility Conclusion X X      
Weight X X     X 
Height X       
Medical History/Prior Medications X X      
Vital Signs (blood pressure, pulse 
rate)  X X X X X X X 
Urine Pregnancy Test (for females 
of childbearing potential) X X X X X X X 
IGA X X X X X X X 
CEA X X X X X X X 
Lesion count X X X X X X X 
RosaQoL & DLQI Score  X X X X X X 
Physical Examinationa X      X 
Laboratory assessments (Blood & 
Urine tests) X b      Xc 
Photographyd  X X X X X X 
Randomization  X      
Dispense/ Re-dispense Study Drug  X Xe X X X  
Dispense/Review/Collect Study 
Diary  X X X X X X 
Discussion of Su bject Instructions  X X X X X  
Collect Study Drug   Xe X X X X 
Evaluate Study Drug Compliance   X X X X X 
Adverse Event 
(Assessment/Collection)  X X X X X X 
Concomitant Medication   X X X X X 
CEA = Clinicianâ€™s Erythema Assessment; DLQI  = Dermatology Life Quality Index; EOS  = end of study; 
IGA = Investigatorâ€™s Global Assessment modified scale without erythe ma; RosaQoL = Rosacea Quality of Life 
 
a A complete physical examination will be performed. Heig ht and weight will be measured at Screening. 
Weight will also be measured at Baseline and Visit 7 (EOS or ET) 
b Serology assessments will be performed only at Screening. 
c Laboratory assessments (except Serology) for all s ubjects will be done at their EOS visit (Week 16). 
d Photography will be done at a subset of sites. 
e Collect and Re-dispense at Visit 3  		


	
[CONTACT_23015]â€™s /Journey Medical Page 9 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 4 TABLE OF CONTENTS 
1 TITLE PAGE .................................................................................................................... ......1  
2 SPONSOR/CRO SIGNATURE [CONTACT_1783] .................................................................................[ADDRESS_122453] Discontinuation Criteria ................................................................................23  
8.3.4  Replacement of Subjects ............................................................................................25  
8.4 Treatments .................................................................................................................... .....25  
8.4.1  Dosage and Formulations ..........................................................................................25  
8.4.2  Method of Treatment Assignment, Randomi zation, and/or Stratification .................[ADDRESS_122454] ........................................................27  
8.4.4  Blinding of Study Medication ....................................................................................27  
8.4.5  Method of Packaging, Labeling, Storage, and Dispensing ........................................27  
8.4.6  Replacement of Study Medication .............................................................................28  
8.4.7  Study Medication Accountability ..............................................................................28  
8.4.8  Prior and Concomitant Medications ..........................................................................29  
[IP_ADDRESS]  Medications, Supplements, and Other Substances Prohibited Before Study Entry 
and During the Study ..................................................................................................... 29  
[IP_ADDRESS]  Other Restrictions .......................................................................................................... 2 9 
[IP_ADDRESS].1  Sun Exposure .............................................................................................................. 29  
[IP_ADDRESS].2  Contraceptives ............................................................................................................ 29  
[IP_ADDRESS]  Concomitant Medications, Supplements, and Other Substances Allowed During 
the Study ..................................................................................................................... ... 30  		


	
[CONTACT_23015]â€™s /Journey Medical Page 10 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 8.4.9  Assessment of Compliance ........................................................................................30  
8.5 Study Schedule ................................................................................................................ ..30 
8.6 Study Procedures .............................................................................................................. 30 
8.6.1  Study Initiation...........................................................................................................31  
8.6.2  Written Informed Consent .........................................................................................31  
8.6.3  Significant Medical History/Demographic Information ............................................31  
8.6.4  Physical Examination (Including Vital Signs) ...........................................................[ADDRESS_122455] and Acceptable Contraceptive Methods ................................32  
8.6.8  Investigatorâ€™s Global Assessment (IGA)  ...................................................................33  
8.6.9  Clinicianâ€™s Erythema Assessment (CEA)  ..................................................................33  
8.6.10  Total Inflammatory Lesion Count .............................................................................34  
8.6.11  Rosacea Quality of Life (RosaQoL) ..........................................................................34  
8.6.12  Dermatology Life Quality Index (DLQI) ..................................................................34  
8.6.13  Photography ...............................................................................................................34  
8.6.14  Review Inclusion/Exclusion Criteria .........................................................................[ADDRESS_122456], and Compliance .....................................................35  
8.6.17  Adverse Events and Serious Adverse Events Assessment ........................................35  
8.6.18  Concomitant Medication Review ..............................................................................35  
8.6.19  Study Medication Accountability ..............................................................................35  
8.7 Visit-Specific Procedures ..................................................................................................35  
8.7.1  Visit 1/Day -30 to -3: Screening ................................................................................35  
8.7.2  Visit 2/Day -1: Baseline .............................................................................................36  
8.7.3  Visit 3/Day 14 (Â± 3 days), Visit 4/Day 29 (Â± 3 days), Visit 5/Day 57 (Â± 5 days), 
and Visit 6, Day 85 (Â± 5 days) ................................................................................................ 37 
8.7.4  Visit 7/Day 113 (Â± 5 days): End of Study or Early Termination ...............................37  
8.7.5  COVID-19 Considerations.........................................................................................38  
8.8 Efficacy Assessments ........................................................................................................39  
8.8.1  Co-Primary Efficacy Endpoints .................................................................................39  
8.8.2  Secondary Efficacy Endpoints ...................................................................................39  
8.8.3  Exploratory Efficacy Endpoints .................................................................................39  
8.9 Assessment of Safety ........................................................................................................39  
8.9.1  Safety Endpoints ........................................................................................................39  
8.9.2  Definitions of Terms ..................................................................................................40  
[IP_ADDRESS]  Adverse Event ................................................................................................................ 40 
[IP_ADDRESS]  Suspected Adverse Reaction .......................................................................................... 41  
[IP_ADDRESS]  Unexpected Adverse Event ............................................................................................ 41  
[IP_ADDRESS]  Serious Adverse Event ................................................................................................... 41  
[IP_ADDRESS]  Planned Hospi[INVESTIGATOR_059] ................................................................................................. 42  
[IP_ADDRESS]  Pregnancy ..................................................................................................................... . 42 
8.9.3  Monitoring Adverse Events and Laboratory Evaluations ..........................................42  
8.9.4  Assessment of Adverse Events ..................................................................................43  
[IP_ADDRESS]  Assessment of Severity .................................................................................................. 43  
[IP_ADDRESS]  Assessment of Causality ................................................................................................ 43  
8.9.5  Reference Safety Information for Assessing Expectedness of Adverse Events ........44  		


	
[CONTACT_23015]â€™s /Journey Medical Page 11 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 [IP_ADDRESS]  Known Potential Toxicities of Investigational Product ................................................. 44  
8.9.6  Reporting Safety Observations ..................................................................................44  
8.9.7  Discontinuation, Treatment Interruption, and Unblinding of Blinded Treatment 
Due to Safety Observations .................................................................................................... .47 
[IP_ADDRESS]  Discontinuation .............................................................................................................. 47 
[IP_ADDRESS]  Treatment Interruption ................................................................................................... 47  
[IP_ADDRESS]  Modification of Dose of Study Medication ................................................................... 47  
[IP_ADDRESS]  Unblinding Treatment for a Subj ect During the Study .................................................. [ADDRESS_122457] (IRB) .....................................................................................[ADDRESS_122458] Confidentiality .....................................................................................................53  
10.4  Study Registration ............................................................................................................ .53 
11 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] ................................................................53  
11.1  Site Regulatory Documents Required for Initiation .........................................................53  
11.2  Maintenance and Retenti on of Records ............................................................................54  
11.2.1  Electronic Case Report Forms (eCRFs) .....................................................................[ADDRESS_122459] OF REFERENCES .....................................................................................................57  
14 INVESTIGATOR AGREEMENT ......................................................................................60  
15 APPENDICES .................................................................................................................... ...61  		


	
[CONTACT_23015]â€™s /Journey Medical Page 12 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122460] of Tables 
Table 8.1  Prohibited Topi[INVESTIGATOR_110136], Systemic Drugs, and Other Treatments ......................21  
Table 8.2:  Identity of Test .......................................................................................................25  
Table 8.3:  Identity of Placebo .................................................................................................26  
Table 8.4:  Identity of Doxycycline capsules 40 mg ................................................................26  
Table 8.5:  Laboratory Tests ....................................................................................................32  
  		


	
[CONTACT_23015]â€™s /Journey Medical Page 13 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122461] OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Term Definition 
AE Adverse event 
ANCOVA Analysis of Covariance 
ANOVA Analysis of variance 
CEA Clinicianâ€™s Erythema Assessment  
CFR Code of Federal Regulations 
CI Confidence interval 
CMH Cochran-Mantel-Haenszel test 
COVID-[ADDRESS_122462] research organization 
CRP C-reactive Protein 
DFD-29 Minocycline HCl (formulated as Extended Release capsules) 
DLQI Dermatology Life Quality Index 
eCRF Electronic case report form 
EDC Electronic data capture 
EOS End of study 
ET Early Termination 
FDA US Food and Drug Administration 
GCP Good Clinical Practice 
HCl Hydrochloride 
HDPE High-density polyethylene 
HIV Human immunodeficiency virus 
ICF Informed consent form 
ICH International Council for Harmonization 
IGA Investigatorâ€™s Global Assessment modified scale without erythema 
ITT Intention to treat 
IRB Institutional review board 
IUD Intrauterine device 
IWRS Interactive web response system 
MedDRA Medical Dictionary for Regulatory Affairs 
MI Multiple imputation 
MMRM Mixed model repeated measures 
MVOR-1 Minocycline Versus Oracea in Rosacea â€“ Study 1 
OTC Over the counter 		


	
[CONTACT_23015]â€™s /Journey Medical Page 14 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 Term Definition 
PI [INVESTIGATOR_110137]-emergent adverse event 
US [LOCATION_002]  
 		


	
[CONTACT_23015]â€™s /Journey Medical Page 15 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 6 INTRODUCTION 
6.1 Background 
Rosacea is a chronic relapsing inflammatory cutane ous disorder, primarily of the convexities of 
the central face (cheeks, chin, nos e, and central forehead). The main clinical forms of the disease 
are erythematotelangiectatic rosacea (subtype 1), papulopustular rosacea (subtype 2), phymatous 
rosacea (subtype 3), and ocular rosacea (subtype 4) [ 25]. In addition to the classification system, 
the National Rosacea Society Expe rt Committee on the Classifi cation and Staging of Rosacea 
devised a standard method for assessing gr adations of the severity of rosacea [ 26]. This standard 
grading system is essential to perform researc h, analyze results, and compare data; provides a 
common reference for diagnosis, treatment, and asse ssment of results in clinical practice; and is 
the basis for the Investigatorâ€™s Global Assessment in rosacea.  
The accurate incidence of rosacea is not known but it is estimated by [CONTACT_110171] 16 million Americans suffer from the signs and symptoms of rosacea, and millions more may be in temporary remission [ 17]. An earlier preliminary study conducted in the US in 
2993 women aged between 10 and 70 years found a prevalence rate for rosacea of 16% in 
Caucasian women and an overall rosacea incidence of nearly 10% in the total population including 
Hispanics, African-Americans, Asians, and Indians [ 23]. A recent epi[INVESTIGATOR_110138] 1.6 5 per 1000 person-years in the [LOCATION_008] 
[18]. In 3052 and 3013 subjects aged between 18 and 65 years drawn from the general populations 
of [LOCATION_013] and Russia, respectively, the preva lence of rosacea was found to be 12.3% (95% 
confidence interval [CI], 10.2-14.4) in Germ any and 5.0% (95% CI, 2.8-7.2) in Russia [ 21]. In a 
Swedish study in a non-selected population of 80 9 office employees (454 women and 309 men), 
81 people were diagnosed as having rosacea givi ng a prevalence of 10% (women 14%, men 5%) 
[2]. In a cross- sectional study of 348 subjects randomly selected from a working population â‰¥ 30 
years of age in Estonia, 78 (22%) had one  or more primary features of rosacea [ 1]. Rosacea is a 
chronic skin condition that disproportionately affects fair-skinned persons of European and Celtic 
origin. 
The pathogenesis of rosacea is poorly understood. Contributing factors may include immune and 
inflammatory abnormalities, vasc ular alterations, neurogenic dysregulation, presence of cutaneous 
microorganisms, ultraviolet (UV) damage, and skin barrier dysfunction [ 10, 14, 20, 24, 27]. 
Clinical features and trigger factors of rosacea indicate a complex dysregulation of inflammatory, 
vascular, and neuronal systems at  an early stage. Elevated leve ls of antimicrobial peptides 
(cathelicidins), processing enzymes (epi[INVESTIGATOR_110139] 5), proinflammatory 
cytokines, and toll-like receptors (TLR) seem  to play a role in maintaining chronic inflammation 
in rosacea, which may induce modification of dermal structures mediated by [CONTACT_110172]. Complex vascular m echanisms contribute to local vasodilation, 
angiogenesis, and tissue fibrosis in rosacea. Th e involvement of the nervous system is supported 
by [CONTACT_110173]. 
Consistent with its immuno-inflammatory and neurovascular pathophysiology, rosacea was found 
to be associated with seve ral autoimmune diseases [ 8], with cardiovascular disease risk factors and 
cardiovascular diseases [ 7, 15], with migraine [ 19], and with a 2- to 5-fold increased risk of 
depression and anxiety disorders [ 9, 13]. In addition, almost half of the rosacea subjects report a 
significant impairment in  their quality of life [ 3, 21]. Taking into consideration these findings and 
that about 50% of the subjects receive no rosacea care, effective treatmen t might contribute not 		


	
[CONTACT_23015]â€™s /Journey Medical Page 16 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122463] as oxygen scavengers, and impr ove epi[INVESTIGATOR_110140]. All of these 
biological activities could contribute to the ef fectiveness of low-dose tetracyclines in rosacea 
treatment. The use of tetracyclines was also found to be associated with a decreased incidence of 
vascular disease in veterans with rosacea [ 6]. 
Details about specific benefits and risks for subjec ts participating in this study may be found in the 
accompanying consent documents for this study.  
The study will be conducted in compliance with  the protocol, Good Clinical Practice (GCP), and 
all applicable regulatory requirements. 
6.2 Rationale for the Study and Study Design 
6.2.1 Study Rationale 
This is a Phase 3 multicenter, randomized, dou ble-blind, parallel-group, active and placebo-
controlled study to assess the efficacy, safety and tolerability of oral DFD-29 (Minocycline 
Hydrochloride Extended Release Capsules), 40 mg (hereafter referred to as DFD-29) for the 
treatment of papulopustular rosacea over [ADDRESS_122464] comm on form of the disease and represents a more 
inflammatory subtype. Papulopustular rosacea is ch aracterized by [CONTACT_110174]  a central facial distribution, but it can also 
present with telangiectasias (usually masked by [CONTACT_110175][INVESTIGATOR_110141]) and can occur 
concomitantly with acne vulgaris [ 25, 27]. Although multiple therapeutic options are available for 
the treatment of papulopustular ros acea, the most widely used systemic agents are oral tetracycline 
derivatives, particularly doxycycline and minocycline. 
The main concern with the long-term use of te tracyclines in rosacea ha s been antibacterial 
resistance. However, the recent findings that tetr acyclines exert anti-inflammatory effects and 
seem to be effective in papulopustular rosacea at  low sub-antimicrobial doses opens new options 
for its clinical use in this indication that warrant further investigation [ 10, 11, 12, 22]. Doxycycline 
and minocycline show a variety of biological actions independent of their antibiotic activity, 
including scavenging of oxygen radicals, anti -inflammatory and anti-apoptotic actions, and 
inhibition of proteolysis, angiogenesis, and tumor growth. Tetracyclines may reduce the 
inflammation associated with rosacea by  [CONTACT_110176] [ 10, 11, 12]. 
Minocycline modulates glutamate-induced excitotoxi city and has anti-apoptotic, antioxidant, anti-
inflammatory, and neuroprotective effects th at proved beneficial in experimental models of 
various diseases with an inflammatory basis, including dermatological, autoimmune, vascular, 
psychiatric, and neurological conditi ons, for which it has been postulated as an adjunctive therapy 
[4, 11, 12]. The lack of photosensitivity represents a potential advantage of minocycline for the 
treatment of papulopustular rosacea because doxycyc line exhibits a dose-related phototoxicity [ 5]. 
Minocycline demonstrated benefit in the trea tment of inflammatory lesions in subjects with 
rosacea [ 16, 22] and proved remarkably effective in de creasing serum C-reactive protein (CRP) 		


	
[CONTACT_23015]â€™s /Journey Medical Page 17 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 levels in other conditions [ 18]. However, the dose-related efficacy of minocycline at sub-
antimicrobial doses in improving the clinic al symptoms and reducing serum CRP in 
papulopustular rosacea has not been investigated. 
[CONTACT_23015]â€™s completed a Phase 2 study in November 2018, which evaluated the efficacy, safety, 
and tolerability of DFD-29 for the treatment of papulopustular rosacea over 16 weeks, in [LOCATION_013]. 
This study demonstrated a significantly great er efficacy with DFD-29 (40 mg and 20 mg) 
compared to placebo, and with DF D 29 (40 mg) compared to OrayceaÂ® (Doxycycline Capsules 
40 mg) (EU product). Based on the assessment of clinical and laboratory adverse events (AEs) as well as all other safety parameters, DFD-[ADDRESS_122465]. ReddyÂ´s Laboratories Ltd. was safe 
and well tolerated.  
This Phase 3 study is intended to provide eff icacy data across a larger study population with 
approximately 29 study centers in the US. 
6.2.2 Dose Selection 
The proposed dose strength of DFD-29 to be evaluated in this study is 40 mg. The safety, efficacy, 
and tolerability of DFD-29 at doses of 20 mg and 40 mg were evaluated in the Phase 2 study referenced above. Based on the assessment on the clinical and laboratory AEs as well as other safety parameters, DFD-29 (40 mg) demonstrated no significant safety or tolerability issues and therefore is considered to be safe and well tolera ted when used in subjects with rosacea. 
Minocycline, along with doxycycline and tetracyc line, has found a place in dermatologistsâ€™ 
therapeutic armamentarium for treatment of inflammatory lesions (papules and pustules) in 
subjects with moderate to severe rosacea; howev er, only a sub-antimicrobial dose of doxycycline 
has been approved in the US for this indication. 
The selection of DFD-[ADDRESS_122466] 		


	
[CONTACT_23015]â€™s /Journey Medical Page 18 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be 
randomized to one of the following treatment groups: 
x DFD-29 (Minocycline HCl Ex tended Release Capsules), 40 mg once daily for 16 weeks 
(DFD-29) 
x  Doxycycline capsules 40 mg once daily for 16 weeks * 
x Placebo capsules once daily for 16 weeks  
* An authorized generic of Ora cea (Doxycycline capsules 40 mg) in the [LOCATION_002] 
(marketed by â€“ Prasco Laboratories , Mason OH [ZIP_CODE] [LOCATION_003]) will be used as the active 
comparator product.  
Subject visits are scheduled at Screening, Baseli ne (Day 1), and Weeks 2, 4, 8, 12, and 16. Clinical 
assessments of efficacy will be conducted  based on Investigatorâ€™s Global Assessment  modified 
scale without erythema (IGA ), Clinicianâ€™s Erythema Assessment (CE A), and total inflammatory 
lesion count at Weeks 2, 4, 8, 12, and 16 compared to Baseline.  
Laboratory assessments of blood (hematology and bi ochemistry) and urine (routine tests) will be 
conducted at Screening and Week 16 (end of study [EOS] or early termination) to assess for any 
changes in the safety paramete rs. Other safety assessments include vital signs, physical 
examination, urine pregnancy tests (for females of  childbearing potential),  and collection of AE 
data. 
The impact of the treatment on the quality of life (QoL) of the subjects will be assessed using the 
rosacea-specific tool RosaQoL in addition to the Dermatology Life Quality Index (DLQI) at 
Baseline and Weeks 2, 4, 8, 12, and 16. 
The study design is appropriate for the indicat ion studied. Validated methods of data collection, 
analysis, and evaluation will be used for the study. 
8.[ADDRESS_122467] is considered to be enrolled in th e study when he/she ha s provided written informed 
consent  and has been randomized to study medication. 
A subject is considered to have completed the st udy after he/she has comp leted Visit 7 (Week 16). 
A subject is considered to have discontinued after he/she has withdra wn consent or has been 
discontinued under the conditions specified in Section 8.3.[ADDRESS_122468] to  follow-up if he/she cannot be contact[CONTACT_24992]. The investigator will document eff orts to attempt to reach the subject twice by 
[CONTACT_94598] a certified letter before considering the subject lost to follow-up. The end of participation for a subject lost to follow-up is  documented as the deli very/return date of the 
certified letter. 
Each subject will be monitored for the occurr ence of AEs, including serious adverse events 
(SAEs), starting immediately afte r the subject has signed the informed consent form (ICF). Each 
subject will be followed for safety monitoring unt il he/she is discharged from the study. Follow-up 
procedures related to pregnancy, AEs, or SAE s may continue beyond the end of the study. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 19 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122469] will participate in  the study for approximately 20 weeks from the time he/she signs 
the ICF through the final contact. After a screen ing phase of approximately [ADDRESS_122470]  18 years of age and with a diagnosis of 
papulopustular rosacea (IGA grade 3[moderate] or grade 4 [severe]) will be selected to participate in the study. 
8.3.[ADDRESS_122471]  meet all of the following criteria to be eligible for the study: 
1. Subjects must be able to understand the require ments of the study and be willing to give 
written informed consent. 
2. Male and female subjects aged [ADDRESS_122472] a clinical diagnosis of papulopustular rosacea with IGA grade 3 
(moderate) or IGA grade 4 (severe) at Baseline. 
5. Subjects must have 15 to 60 (both inclusive ) inflammatory lesions (papules and pustules) 
of rosacea over the face at Baseline.  
6. Subjects must have not more than [ADDRESS_122473] agree to only use the study medi cation and to not use any other treatment for 
rosacea (prescription or over-the-counter [OTC]) during the course of the study. 
8. Subjects must be willing to mi nimize or not significantly cha nge external factors that might 
trigger rosacea flare-ups (such as spi[INVESTIGATOR_99797], thermally hot foods, soups and drinks, hot environments, prolonged sun exposure, strong wi nds, alcoholic beverages, etc.) throughout 
the study. 
9. Subjects must be free of any systemic or de rmatologic disorder that, in the opi[INVESTIGATOR_1070], will interfere with the study resu lts, and especially free of any skin diseases 
(for example peri-oral dermatitis, facial kerato sis pi[INVESTIGATOR_22785], seborrheic dermatitis, and acne 
vulgaris) that may confound the evaluation of rosacea. 
10. Females of childbearing potential must have a negative urine pr egnancy test at the 
Screening and Baseline Visits. Sensitivity of such a test should at least be 25 mIU/mL or 
lower for human chorionic gonadotropin (hCG). 
11. Females must either be postmenopausal with no menses for at least 12 months or surgically 
sterile (hysterectomy or tubal ligation) or agree to use a highly effective method of 
contraception with a pearl index of <1% up to [ADDRESS_122474] dose. Contraception 
methods with low user dependency should preferably be used, in particular when 
contraception is introduced as a result of participation in this clinical study.  
â€˜Highly effectiveâ€™ methods of birth control include:  		


	
[CONTACT_23015]â€™s /Journey Medical Page 20 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 x combined (estrogen and progesterone containing) hormonal contraception 
associated with inhibition of ovulation*: 
o oral 
o intravaginal 
o transdermal 
x progesterone-only hormonal contraception associated with inhibition of 
ovulation*: 
o oral 
o injectable 
o implantableâ€   
x intra- uterine device (IUD) â€   
x intra- uterine hormone releasing system (IUS) â€   
x bilateral tubal occ lusionâ€   
x vasectomy of sexual partner th at was performed at least 90 days prior to Baseline, 
and has been medically assessed as successfulâ€   
x total (as opposed to periodic or cyclic) sexual abstinence 
o Note: Sexually inactive female s ubjects may be enrolled at the 
investigatorâ€™s discretion provided that they are counseled to refrain from heterosexual intercourse for the dura tion of the study and for one month 
after the last dose, and understand the possible risks involved in getting 
pregnant during the study. 
* Hormonal methods: If on hormonal contra ceptives, must have been on the 
same hormonal contraceptive product for  3 months (90 days) prior to 
Baseline and continued on th e same method and dose throughout the 
duration of the study. If subject had used hormonal birth control and had 
stopped, this should have occurred more  than 6 months prior to Baseline. 
Female subjects on low dose oral contraceptives (containing â‰¤35 Î¼g of 
ethinyl estradiol or equivalent dose of other estrogens) must use a second 
form of contraceptive during the study. 
â€  Contraception methods that are considered to have low user dependency.  
8.3.2 Exclusion Criteria 
Subjects who meet any of the following cr iteria will be excluded from the study: 
1. Female subjects who are pregnant or nursing or planning to become pregnant during the 
study. 
2. Male subjects whose female partner is planning to conceive a child. 
3. Clinically significant abnormal laboratory tes t results that, in the opi[INVESTIGATOR_1070], would compromise the subjectâ€™s safety or ab ility to participate in the trial. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 21 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 4. History of organ transplant requiring imm unosuppression, HIV, or other immune 
compromised state. 
5. History of lupus-like syndrome, autoimmune hepatitis, vasculitis, or serum sickness. 
6. Use of any treatment listed in Table  8.1 more recently than the indicated washout period 
prior to Baseline (Visit 2/Day 1). 
Table 8.[ADDRESS_122475] Washout period before Baseline 
Topi[INVESTIGATOR_110142] 30 days 
Retinoids (e.g., tretinoin, adapalene, retinol, tazarotene) and 
other cosmetic retinoids) 30 days 
Immunomodulators (including topi[INVESTIGATOR_22726] 
[e.g. ProtopicÂ® (tacrolimus) ointment])  30 days 
Anti-inflammatory agents or  topi[INVESTIGATOR_15385]-steroidal anti-
inflammatory drugs (NSAID) 14 days  
Topi[INVESTIGATOR_110143] 14 days 
Benzoyl peroxide, Sodium Sulfacetamide 10%, Sulfur 5%  14 days 
Topi[INVESTIGATOR_8163] (e.g., ZilxiÂ®  (minocycline) topi[INVESTIGATOR_110144], 
macrolides, clindamycin) 14 days 
Any anti- rosacea topi[INVESTIGATOR_12969] (e.g., metronidazole, 
azelaic acid, brimonidine, ivermectin, oxymetazoline) 14 days 
Medicated cleansers (e.g., benz oyl peroxide, salicylic acid, 
sulfur or triclosan) 7 days 
Astringents or abrasives (O TC scrubs, exfoliating cleansers 
and products containing salicylic acid and alcohol) 7 days 
Anti-microbial soaps and face wash Not applicable (use should be 
discontinued at baseline) 
Systemic Treatments 
Oral Retinoids [e.g., AccutaneÂ®] or therapeutic vitamin A 
supplements of >10,000 units per day 180 days 
Radiation therapy and/or anti-neoplastic agents 90 days 
Beta-blockers â€“ use must remain cons tant during the study Initiation of therapy or change of 
dose within 90 days 
Hormonal treatment (oral, imp lant, topi[INVESTIGATOR_110145]) â€“ use must remain constant during the study Initiation of therapy or change of 
dose within 90 days 
Vitamin D supplements of > 4,000 units/day or >100 m cg 
(daily multivitamins with Vitamin D not exceeding more 
than 4,000 IU/day are allowed) 
A constant stable prescribed weekly dose is allowed and 
subjects should remain on th is dose during the study 30 days 		


	
[CONTACT_23015]â€™s /Journey Medical Page 22 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122476] rosacea (e.g., t etracyclines, 
minocycline, doxycycline, metronidazole, or macrolides) 
Short- term treatment of all other antibiotics (not affecting 
rosacea) for â‰¤14 days is acceptable  30 days 
Corticosteroids  â€“ Intranasal and inhaled corticosteroids are 
allowed and may be used throughout the study if at a stable 
dose. [ADDRESS_122477] 30 days prior to 
randomization  Initiation of therapy or change of 
dose within 30 days 
Other systemic drugs used for treatment of rosacea 30 days 
Barbiturates 30 days 
Rifampi[INVESTIGATOR_2513] 30 days 
Carbamazepi[INVESTIGATOR_050] 30 days 
Phenytoin (diphenylhydantoin) 30 days 
Primidone 30 days 
Cyclosporin 30 days 
Methoxyflurane or other nephrotoxic drugs 30 days 
Nonsteroidal anti-inflam matory drugs (NSAIDs) 
(except aspi[INVESTIGATOR_110146] < 325 mg once daily 
for subjects requiring platelet aggregation inhibition)  
Chronic use of NSAIDs  
(> 14 days) other than low- dose aspi[INVESTIGATOR_110147]. 7 days 
Niacin at doses > 500 mg /day 7 days 
Other Treatments 		


	
[CONTACT_23015]â€™s /Journey Medical Page 23 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122478] Washout period before Baseline 
Use on the face of the following:  
Cryodestruction or chemodestruction Dermabrasion 
Photodynamic therapy 
Acne Surgery Intralesional steroids Laser resurfacing or electrodessication 
X-ray therapy 
Laser: Non-ablative lasers, Vascular (Pulse dye laser
s 585 
and 596 nm) lasers, multichromatic lasers, long- pulsed Nd-
YAG laser Intense pulse light (IPL) or pulse light laser Electrocautery or electrocoagulation CO
2 laser, Fractioned lasers, or loop electrosurgery 
Facial peels or other facial co smetic surgery (e.g. Thermage, 
etc.)  30 days 
Use of tanning booths, sun lamp s, or excessive UV radiation 
(e.g. phototherapy, daily exten ded exposure or occupational 
exposure to the sun), sunbathing or excessive exposure to sun  [ADDRESS_122479]â€™s ability to comply with study requirements  and/or have drug or alcohol 
addiction requiring treatment in the past 12 months. 
10. Any clinically significant condition or situation other than the condition being studied that, 
in the opi[INVESTIGATOR_871], would interf ere with the study evaluations or optimal 
participation in the study. 
11. Use of any investigational drugs within 90 da ys prior to Baseline (Visit 2/Day 1). 
12. Participation in any other clinical study within [ADDRESS_122480] may discontinue from the study at any time for any reason. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 24 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122481] will be discontinued from the study if his/ her safety or well-being is determined to be at 
risk. Discontinuation will be made at the discretion of the investigator or at the subjectâ€™s request.  
A subject must be discontinued from the study  and study medication for any of the following 
reasons: 
x The subject or legal representative withdraws consent 
x The subject becomes pregnant 
x The subjectâ€™s medication code is unblinded  
x There is a significant protocol violation or non-compliance with the protocol 
A subject may be discontinued from the study for any of the following reasons: 
x AE, including intercurrent illness, for which the subject desires to discontinue treatment or 
the investigator determines that it is in the subjectâ€™s best interest to be discontinued  
x Condition worsens and requires alternative or supplemental therapy for treatment of 
rosacea during the study 
x Noncompliant use of the study medication 
x Lost to follow-up 
x Investigator discretion 
Discontinuation is permanent; after a subject has be en discontinued, he/she will not be allowed to 
enroll again. 
If a subject is discontinued from the study for an y reason, the Visit 7 (EOS or early termination) 
procedures should be completed and any outst anding data and study medication should be 
collected. Data, including the date and primary r eason for discontinuation, must be documented 
on the EOS electronic case report form (eCRF) and source document.  
If a subject discontinues the study at any time du e to an AE, the reason for discontinuation, the 
nature of the AE, and its clinical course must be fully documented. The investigator must strive to 
follow the subject until the AE has resolved, b ecome clinically insignificant, is stabilized, or the 
subject is lost to follow-up. For any SAE, follow procedures provided in Section 8.9.[ADDRESS_122482]â€™s case record form and included 
in the study report.  Any decision by [CONTACT_110177] a subject from the study for 
reasons of violation of inclusion/exclusion criteri a or protocol deviations should be discussed with 
the CRO/Sponsor medical monitor, as far as possible, prior to discontinuing the subject. 
As far as possible, investigators must advise s ubjects to refrain from consuming the prohibited 
medication (as specified in Table 8.1 ). In case a subject consumes  a prohibited concomitant 
medication or needs to take one, a joint decision will be taken by [CONTACT_110178] s ubject should continue in the study or be 
withdrawn, depending upon the potential for harmfu l drug-drug interaction and influence on study 
efficacy assessments. The investigator mu st communicate information about the drug 
taken/required by [CONTACT_1130], including its generic na me, dose and duration of treatment and reason 
for subject taking/being advised to take the drug, as  soon as it comes to his/her knowledge, to CRO 		


	
[CONTACT_23015]â€™s /Journey Medical Page 25 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122483] will be discontinued 
immediately, and she will be followed throug h the pregnancy and de livery. Details of the 
pregnancy, delivery and health of the infant should be recorded  on the Pregnancy Report Form 
and the sponsor should be notified immediately. 
If the sponsor terminates or suspends the study , the investigator or his/her designee should 
promptly inform the IRB (and/or regulatory aut horities where required) of a temporary halt 
including the reason for such an action. 
8.3.[ADDRESS_122484]. Reddyâ€™s  
Laboratories Ltd. To maintain the double-blind de sign, all 3 study medications will be over-
encapsulated with the original capsules enclosed within a second, larger (size 0) capsule shell. 
Table 8.2:  Identity of Test  
 Test treatment 
Name: [CONTACT_110226]-29 (Minocycline HCl Extended Release 
Capsules ) 
Active ingredient: Minocycline HCl 
Formulation: Extended Release Capsules 
Dose strength: 40 mg minocycline 
Dose: 1 capsule 
Posology: Once daily, in the morning 
Mode of administration: Oral administration with approx. 240 mL water 
Administration condition: Fasting state preferred, but not mandatory 
Duration of administration: 16 weeks 		


	
[CONTACT_23015]â€™s /Journey Medical Page 26 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122485] treatment 
Batch number & Expi[INVESTIGATOR_5695]: Will be given in the Tria l Master File (TMF) ***. 
*** The documentation allowing traceability will be provided in the TMF. 
Table 8.3:  Identity of Placebo  
 Placebo treatment 
Name: [CONTACT_110227]-29 
Active ingredient: Not applicable 
Formulation: Capsules 
Dose strength: Not applicable 
Dose: 1 capsule 
Posology: Once daily, in the morning 
Mode of administration: Oral administration with approx. 240 mL water 
Administration condition: Fasting state preferred, but not mandatory 
Duration of administration: 16 weeks 
Batch number & Expi[INVESTIGATOR_5695]: Will be given in the TMF ***. 
*** The documentation allowing traceability will be provided in the TMF. 
Table 8.4:  Identity of Doxycycline capsules 40 mg 
 Doxycycline capsules 40 mg treatment 
Name: [CONTACT_110228] 40 mg 
Active ingredient: Doxycycline anhydrous 
Formulation: Capsule with 30 mg immediate release and 10 mg 
delayed release beads  
Dose strength: 40 mg doxycycline 
Dose: 1 capsule 
Posology: Once daily, in the morning 
Mode of administration: Oral administration with approx. 240 mL water 
Administration condition: Fasting state preferred, but not mandatory 
Duration of administration: 16 weeks 
Batch number & Expi[INVESTIGATOR_5695]: Will be given in the TMF ***. 
*** The documentation allowing traceability will be provided in the TMF. 
 		


	
[CONTACT_23015]â€™s /Journey Medical Page 27 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 8.4.2 Method of Treatment Assignment, Rand omization, and/or Stratification 
Upon screening, the subject will be assigned a unique 5-digit subject number preceded by [CONTACT_110179] 
â€œSâ€, where the first [ADDRESS_122486] number that 
increments sequentially at  the site (i.e., S10-001, S10-002).   At the Baseline Visit (Visit 2/Day 1), 
subjects eligible for participation will retain the same subject number without the letter â€œSâ€ 
preceding it (i.e., 10-001, 10-002).  All subjects will  retain this subject number for the remainder 
of the study.  Each subject will be dispensed a total of 4 bottles and will be randomly assigned a 
unique bottle number at each visit study medication is dispensed (Visit 2/ Day 1, Visit 4/Day 29, 
Visit 5/Day 57 and Visit 6/Day 85), using the Interactive Web Response System (IWRS). 
Subjects who satisfy all of the inclusion and none of the exclusion criteria will be randomized in a 
3:3:[ADDRESS_122487]. One capsule 
of the assigned study medication will be swallowed with 240 mL (1 glass) of still water on an 
empty stomach.  
Substances that can potentially interfere with  absorption of minocycline like antacids, 
multivitamins, or other products containing aluminum, magnesium and calcium, oral iron 
preparations, bismuth subsalicylate, and milk and other dairy products should be avoided from 1.5 
hours before to 3.0 hours after intake of study medication. 
The dosage regimen in this study is that approved for Doxycycline capsules 40 mg [ 28].  
8.4.4 Blinding of Study Medication 
A double-blind technique will be used. DFD-29, its matching placebo, and Doxycycline capsules 
40 mg are indistinguishable after over-encapsulati on. The investigator and study staff (including 
lab personnel), the subjects, the monitors, med ical monitors, the CRO personnel involved in 
clinical operations, and the s ponsorâ€™s staff will remain blinded to the treatment until study closure.  
See Section [IP_ADDRESS]  for a description of the method of unblinding a subject during the study if such 
action is warranted. 
8.4.5 Method of Packaging, Labelin g, Storage, and Dispensing 
Study medications will be supplied in high-den sity polyethylene (HDPE) bottles containing 
[ADDRESS_122488] will be dispensed a total of 4 bot tles and will be randomly assigned a unique bottle 
number at each visit study medicat ion is dispensed (Visit 2/Day 1, Visit 4/Day 29, Visit 5/Day 57 
and Visit 6/Day 85), using the IWRS. 
At the Visit 2/Day 1, each subject enrolled will  receive 1 bottle of study medication. At Visits 
4/Day 29, 5/Day 57, and 6/Day 85, the study me dication will be collected, and 1 new bottle of 
study medication will be dispensed.  Study medication will be collected and re-dispensed at Visit 
3/Day 14. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 28 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122489] packaging and to maintain double-blinding, the investigator/sub-investigator performing the study clinical assessments will not be involved with the dispensing or return of study medication.   
At the minimum, the following information will be stated on the labels: 
x Study number (DFD-29-CD-004) 
x Visit No. 
x Bottle number 
x Subject number and initials 
x Amount (35 capsules of either DFD-29 40 mg / Placebo / Doxycycline capsules 40 mg) 
x Sponsorâ€™s Name [CONTACT_1781] 
x CROâ€™s Name [CONTACT_1781]  
x Route of administration (e.g., oral) 
x Directions for use 
x Storage conditions 
x â€œFor clinical trial use onlyâ€ or similar cautionary statement  
x â€œKeep out of reach of childrenâ€ or similar cautionary statement  
All study medication will be stored at controlle d room temperature 68Â° - 77Â°F (20Â° - 25Â°C) with 
excursions permitted between 59Â° - 86Â°F (15Â° - 30Â°C), in a climate-cont rolled, limited access area. 
The investigator agrees to store and dispense the study medication only at the site(s) listed on Form 
FDA 1572 (or investigator agreement/statement). The investigator, sub-investigator(s), or qualified designees also agree that the study med ication will be dispensed only to subjects who 
have provided written informed c onsent and have met all entry criteria. Clinical supplies may not 
be used for any purpose other than as stated in the protocol. 
See the Study Flow Chart in Section 3.[ADDRESS_122490] number/initials and the 
initials and date of the person dispensing and receiving the returned medication will be 
documented on this form. 
Inventory records must be readily available for in spection by [CONTACT_68601]/or auditor, and 
open to inspection by [CONTACT_108889]. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 29 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122491]â€™s documented medical history, 
prophylaxis, or an AE. 
[IP_ADDRESS]  Medications, Supplements, and Other Substances Prohibited Before Study Entry and 
During the Study 
The medications prohibited prior to Baseline  are listed in Table 8.[ADDRESS_122492] not take 
during the study, from Visit 2 through Visit 7 (EOS or early termination). 
Substances which can potentially interfere with  absorption of minocycline like antacids, 
multivitamins or other products containing al uminum, magnesium and calcium, oral iron 
preparations, bismuth subsalicylate and milk and ot her dairy products should be avoided from 1.[ADDRESS_122493] udy or be withdrawn, depending upon the potential for 
harmful drug-drug interaction and influence on study efficacy assessments. 
[IP_ADDRESS]  Other Restrictions 
[IP_ADDRESS].1  Sun Exposure 
Excessive sun exposure and/or UV radiation shoul d be avoided, and protective measures should 
be taken. 
[IP_ADDRESS].2  Contraceptives 
Special attention has to be paid to female  subjects taking low dose oral contraceptives 
(35 micrograms of ethinyl estradiol or equivalent dose of other estrogens) as their effectiveness 
may be affected by [CONTACT_110180]-29. To avoid contraceptive failure, female subjects who are taking low dose oral contraceptives have to use a second acceptable form of contraceptive from 
Screening up to [ADDRESS_122494] dose. 
Note:  â€˜Acceptableâ€™ method s of contraception include double barrier methods (e.g. a combination 
of male condom with either, cap, diaphragm or sp onge with spermicide) in addition to the 
â€œhighly effective birth control methods that are described in Section  8.3.1 , inclusion criterion 10.  
Please refer to inclusion criterion 10 (Section  8.3.1 ) for further details on contraception for 
females.  		


	
[CONTACT_23015]â€™s /Journey Medical Page 30 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 [IP_ADDRESS]  Concomitant Medications, Supplements, a nd Other Substances Allowed During the 
Study 
Medications necessary for the health and well-bei ng of the subject are permitted. The use of any 
medication that could affect the course of rosa cea is prohibited during the entire study period. 
Subjects should be instructed to refrain from mak ing any significant change in the use of consumer 
products (including facial cleanser, make-up, bla nd non-medicated emollients or moisturizers, 
etc.) during the course of the study. 
Multivitamins and acetaminophen for pa in relief may be used as needed throughout the study. 
8.4.[ADDRESS_122495] whether treatment 
had been taken per protocol in the preceding interv al. If not, the date(s) and reason for each dosing 
noncompliance must be recorded. 
Compliance will be determined from the diary card, on which the subject will be instructed to 
record all doses taken or missed. The number of dose s will be totaled by [CONTACT_110181]. The total number 
of doses taken and/or missed will be determi ned based upon the first dose taken through and 
including the last dose taken. The first and last date s of treatment should be recorded in the eCRF. 
The total of taken and missed doses should also be recorded. By [CONTACT_108], there are no missed 
doses before the first date of treatment or after the last date of treatment. Subjects will be 
considered compliant if they administer at lea st 80% and no more than 120% of doses. Subjects 
who miss [ADDRESS_122496] igator in agreement with the CRO/Sponsor medical 
monitor. 
8.[ADDRESS_122497] is unable 
to attend a visit within the specified window, however, the visit should be scheduled as closely as 
possible to the applicable window. 
8.6 Study Procedures 
The Study Flow Chart in Section 3.2 summarizes the study procedures to be performed at each 
visit. Individual study procedures are described below. 
All clinical assessments (IGA, CEA, and total inflammatory lesion count) must be conducted by 
[CONTACT_110182] [ADDRESS_122498] been delegated these tasks by [CONTACT_28824] (PI). The PI [INVESTIGATOR_110148], physician assistants, or 
nurse practitioners who have documented training a nd past experience conducting the assessment. 
To minimize variability of evaluations, the sa me investigator/sub-investigator should perform 
these assessments for any given subject and anticip ate evaluating the subject at each visit, to the 
extent possible. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 31 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 8.6.1 Study Initiation 
The investigational staff may not enroll any subjects prior to comple tion of an initiation visit. This 
visit will include, but is not limited to, an inventory of study supplies (if present) and a detailed 
review of the protocol, eCRFs, investigator â€™s brochure, and the i nvestigatorâ€™s responsibilities as 
outlined on Form FDA 1572. 
8.6.[ADDRESS_122499]â€™s r ecords. 
At selected study centers, consenting subjects wi ll have lesions on the face photographed at 
Baseline and all subsequent visits . Neither the subject nor the investig ator is permitted to refer to 
the photographs at any subsequent vi sit for the purposes of grading.  
8.6.3 Significant Medical History/Demographic Information 
Significant medical history and demographic inform ation will be obtained at Visit 1 (Screening). 
The medical history will include a complete review  of all current diseases and their respective 
durations and treatments. Demographic information will include date of birth, sex, race, ethnicity, 
and Fitzpatrick skin type. 
For inclusion in the study subjects must have a clinical diagnosis of papulopustular rosacea, IGA 
grade 3 (moderate) or IGA grade 4 (severe). 
Medical history will be reviewed/updated at Visit 2 (Baseline). 
8.6.4 Physical Examination (Including Vital Signs) 
A complete physical examination will be performed  and height, weight, and vital signs recorded 
at Screening to determine that the subject is heal thy enough to participate in the study. Weight will 
also be measured at Visit 2 (Baseline). Physical ex amination and weight will also be performed at 
Visit 7 (EOS or early termination).  
Blood pressure (measured after at least 5 minutes in a sitting position) and pulse rate will be 
measured at every study visit, as part of Vital Signs Assessment. 
8.6.5 Prior Medication Review 
Prior medications (prescription, OTC, and dieta ry supplements), including the necessary washout 
times, will be reviewed with the subject. A reco rd of prior medication taken or used by [CONTACT_49880] 30 days before signing the ICF will be obtai ned. Prior medication will be reviewed/updated 
at Visit 2 (Baseline). 
8.6.6 Laboratory Assessments 
Laboratory tests for hematology, blood chemis try, and urinalysis are specified in Table 8.5 . Blood 
samples for laboratory tests are to be taken pri or to administration of study medication. Blood 
(hematology and chemistry) and urine samples will be  collected at Visit 1 (Screening) and Visit 7 
(EOS or early termination).  Serology for an ti-HIV I, anti-HIV 2, HBsAG, and anti-HCV 
antibodies will only be performed at screening. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 32 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 The samples will be sent to the central labor atory for analysis. Details regarding overall blood 
volume collected, sample handling, processing a nd shipment will be provided in a separate 
laboratory manual.   
Any other investigation (including anti-nuclear antibody and hepatic transaminases for suspected 
drug-induced lupus or auto-immune hepatitis in sy mptomatic subjects) will have to be symptom-
driven or on investigator judgment on a case to case basis. 
Additional safety samples may be taken at investigator discretion in consultation with the Sponsor. 
Table 8.5:  Laboratory Tests  
Hematology Chemistry Urinalysis Others 
Complete Blood Count 
(CBC) including differential count
 Glucose 
Uric acid  
Calcium  
Sodium  
Potassium  
Chloride  
Alkaline phosphatase  
Total bilirubin  
Direct bilirubin 
Creatinine  
BUN  
AST (SGOT)  
ALT(SGPT)  
LDH  
Total protein  
Albumin Urobilinogen 
Nitrites  
pH 
Glucose  
Protein  
Blood  
Ketones  
Pregnancya Serology (for anti-HIV I, 
anti-HIV 2, HBsAG, and 
anti-HCV antibodies)b 
 
ANA (Anti -nuclear- Ab)c 
AST /ALT/GGT (hepatic-
transaminases)c 
a Only required for women of childbearing potential 
b Will o nly be done at scre ening for eligibility  
c Will be done on a case to case basis based on Investigator judgement or symptom-
driven  
 
8.6.[ADDRESS_122500] at Visit 1 
(Screening) and Baseline, prior to randomization, must be willing to use an acceptable form of 
birth control during the study.  
â€˜Highly effectiveâ€™ methods of birth control include  
x combined (estrogen and progesterone containing) hormonal contraception 
associated with inhibition of ovulation*: 
o oral 
o intravaginal 
o transdermal 
x progesterone-only hormonal contraception associated with inhibition of 
ovulation*: 
o oral 
o injectable 		


	
[CONTACT_23015]â€™s /Journey Medical Page 33 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 o implantableâ€   
x intra- uterine device (IUD) â€   
x intra- uterine hormone releasing system (IUS) â€   
x bilateral tubal occlusionâ€   
x vasectomy of sexual partner th at was performed at least 90 days prior to Baseline, 
and has been medically assessed as successfulâ€   
x total (as opposed to periodic or  cyclic) sexual abstinence 
o Note: Sexually inactive female subjects may be enrolled at the investigatorâ€™s 
discretion provided that they are couns eled to refrain from heterosexual 
intercourse for the duration of the study and for one month after the last dose, and understand the possible risks involved in getting pregnant during the study. 
*    Hormonal methods: If on hormonal contra ceptives, must have been on the same 
hormonal contraceptive product for 3 months  (90 days) prior to Baseline and 
continued on same method and dose throughout the duration of the study. If subject 
had used hormonal birth control and had st opped, this should have occurred more 
than 6 months prior to Baseline. Female  subjects on low dose oral contraceptives 
(containing â‰¤35 Î¼g of ethinyl estradiol or equivalent dose of other estrogens) must 
use a second form of contraceptive during the study. 
â€  Contraception methods that are considered to have low user dependency.  
A urine pregnancy test will be performed for women of child-bearing potential at every study visit 
from Screening up to Week 16 (or at early termi nation if previous pregnancy testing was performed 
more than 28 days prior)
. 
8.6.8 Investigatorâ€™s Global Assessment (IGA) 
The IGA (Appendix 15.1) is carried out by [CONTACT_110183]-
investigator at every study visi t from Screening through Week 16 (EOS or early termination). If 
possible, the same study staff member should perf orm the assessment on an individual subject at 
all visits. 
8.6.9 Clinicianâ€™s Erythema Assessment (CEA) 
The CEA (Appendix 15.2) is carried out by [CONTACT_110183]-
investigator at every study visit from Screen ing through Week 16 (EOS or early termination). The 
erythema assessment will be carried out separately at 5 locations on the face: forehead, nose, chin, 
right cheek, and left cheek.    A 2-grade reduction from Baseline to Week [ADDRESS_122501] severe CEA score/s out of the [ADDRESS_122502] severe scores, then the 2-grade reduction has to be on the average scores for those locations 
at Week 16 (for e.g. if the baseline  CEA scores for the right and lef t cheeks are 3, the nose is 1 and 
the forehead and chin are 0 each, the baseline aver age score is equal to 3 for the right and left 
cheeks, then the average of the scores for the two cheeks at Week 16 has to be â€˜1â€™ or below, to be 
considered as at least a 2-grade reduction on the CEA).   		


	
[CONTACT_23015]â€™s /Journey Medical Page 34 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 8.6.10  Total Inflammatory Lesion Count 
The total inflammatory lesion count is carried out by [CONTACT_110184] f at every study visit from Screening through Week 16 (EOS or 
early termination). Inflammatory lesions will be recorded on a diagram of a human face 
(Appendix 15.3) divided in [ADDRESS_122503] at all visits. 
8.6.11  Rosacea Quality of Life (RosaQoL) 
The RosaQoL assessment (Appendix 15.4) will be carried out by [CONTACT_110185] 16 
(EOS or early termination). Subjects  will rate [ADDRESS_122504] that rosacea has on various dimensions  influencing their quality of life.  Calculation 
of the score will be described in the SAP. 
8.6.12  Dermatology Life Quality Index (DLQI) 
The DLQI questionnaire (Appendix 15.5) will be carried out at eve ry study visit from Baseline 
through Week 16 (EOS or early termination). 
The DLQI questionnaire consists of 10 questi ons covering the following topi[INVESTIGATOR_1102]: symptoms, 
embarrassment, shoppi[INVESTIGATOR_110149], clothes, so cial and leisure, sport, work or study, close 
relationships, sexuality and treatment.  Each question refers to the impact of the skin disease on the 
subjectâ€™s life.  
Each question is scored from 0 to 3 and totaled , giving a possible score range from 0 (meaning no 
impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). 
8.6.[ADDRESS_122505] photographs taken at 
study visits (Baseline/Day 1, Visits 2, 3, 4, 5, 6, and 7).  Photographs will be taken of the subjectâ€™s 
face, to document all rosacea lesions that are presen t at Baseline/Day [ADDRESS_122506] enrollment. 
8.6.14  Review Inclusion/Exclusion Criteria 
The inclusion and exclusion criteria will be revi ewed by [CONTACT_110186]. 
8.6.15  Study Medication Dispensing and Collection 
An independent drug dispenser, not involved in the clinical evaluations, will dispense study 
medication to qualified subjects and keep ac curate accountability of all study medication. Study 
medication will be dispensed at Visits 2, 4, 5, and 6 and bottles will be collected at Visits 3, 4, 5, 
6, and 7 to assess compliance and drug accountability.  Study medication will be collected and re-
dispensed at Visit 3.  		


	
[CONTACT_23015]â€™s /Journey Medical Page 35 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122507] use of study medication at the study site during Visit 2 
(Baseline). Subjects will be instructed to take study medication at a fixed time of the day once a 
day for [ADDRESS_122508] udy medication will be swallowed with 240 mL 
(1 glass) of still water on an empty stomach. Addi tional instructions will be reviewed with each 
subject. 
A diary card will be dispensed to each enrolled su bject at Visit 2 (Baseline ). The subject will be 
instructed to complete the diary card to record each dose or missed dose of study medication. At 
subsequent visits, study personnel will review and collect the diary card, and dispense a new diary 
card and re-review subject instructions.  
8.6.17  Adverse Events and Seriou s Adverse Events Assessment 
See Section 8.9 for instructions on the assessment a nd reporting of AEs and SAEs and 
Section 8.9.6  for instructions on reporting SAEs to the sponsor or designee. 
8.6.18  Concomitant Medication Review 
Medications, including prescription, OTC, and di etary supplements (other than study medication) 
taken and other treatments used by [CONTACT_423] d uring the study will be reviewed at each study 
visit. 
8.6.[ADDRESS_122509] number/initials and the 
initials and date of the person dispensing and receiving the returned medication will be 
documented on this form. 
Inventory records must be readily available for in spection by [CONTACT_68601]/or auditor, and 
open to inspection by [CONTACT_108889]. 
8.7 Visit-Specific Procedures 
The following sections outline the procedures required at each visit. 
8.7.1 Visit 1/Day -30 to -3: Screening 
1. Obtain written informed consent (Section 8.6.2 ) 
2. Obtain medical history and demographic information (Section 8.6.3 ) 		


	
[CONTACT_23015]â€™s /Journey Medical Page 36 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 3. Perform physical examination, including hei ght, weight, and vital signs (blood pressure 
and pulse rate) (Section 8.6.4 ) 
4. Obtain/record prior medications (Section 8.6.5 ) 
5. Collect blood and urine for laboratory assessments (Section 8.6.6 ) 
6. Perform urine pregnancy test for all wo men of childbearing potential (Section 8.6.7 ) 
7. Perform IGA (Section 8.6.8 ) 
8. Perform CEA (Section 8.6.9)  
9. Perform lesion count (Section  8.6.10 ) 
10. Evaluate inclusion/exclusion criteria (Section 8.6.14 ) 
11. Schedule next visit 
12. Complete eCRFs (Section 11.2.1 ) 
8.7.2 Visit 2/Day -1: Baseline 
1. Update medical history (Section 8.6.3 ) 
2. Measure weight and vital signs (blood pressure and pulse rate) (Section 8.6.4 ) 
3. Update prior medications (Section 8.6.5 ) 
4. Perform urine pregnancy test for all wo men of childbearing potential (Section 8.6.7 ) 
5. Perform IGA (Section 8.6.8 ) 
6. Perform CEA (Section  8.6.9 ) 
7. Perform lesion count (Section 8.6.10 ) 
8. Perform RosaQoL (Section 8.6.11 ) 
9. Perform DLQI (Section 8.6.12 ) 
10. Evaluate inclusion/exclusion criteria (Section 8.6.14 ) 
11. Randomization (Section 8.4.2 ) 
12. Perform photography of the face on subjects at selected sites (Section 8.6.13)   
13. Dispense study medication and record st udy medication accountability (Sections 8.6.15  
and 8.6.19 ) 
14. Instruct subjects on proper study medic ation administration (Section 8.6.16 ) 
15. Assess AEs (Section 8.6.17 ) 
16. Dispense diary card and re view instructions (Section 8.6.16 ) 
17. Schedule next visit 
18. Complete eCRFs (Section 11.2.1 ) 		


	
[CONTACT_23015]â€™s /Journey Medical Page 37 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 8.7.3 Visit 3/Day 14 (Â± 3 days), Visit 4/Day 29 (Â±  3 days), Visit 5/Day 57 (Â± 5 days), and 
Visit 6, Day 85 (Â± 5 days) 
1. Measure vital signs (blood pressure and pulse rate) (Section 8.6.4 ) 
2. Concomitant medications (Section 8.6.18 ) 
3. Perform urine pregnancy test for all wo men of childbearing potential (Section 8.6.7 ) 
4. Perform IGA (Section 8.6.8 ) 
5. Perform CEA (Section 8.6.9 ) 
6. Perform lesion count (Section 8.6.10 ) 
7. Perform RosaQoL (Section 8.6.11 ) 
8. Perform DLQI (Section 8.6.12 ) 
9. Perform photography of the face on subjects at selected sites (Sections 8.6.15)   
10. Collect and dispense study medication, reco rd study medication accountability, and assess 
compliance (Sections 8.6.15  and 8.6.19 ). Study medication will be collected and re-
dispensed at Visit 3/Day 14. 
11. Assess AEs (Section  8.6.17 ) 
12. Collect and dispense diary card and review instructions (Section 8.6.16 ) 
13. Schedule next visit 
14. Complete eCRFs (Section 11.2.1)  
8.7.4 Visit 7/Day 113 (Â± 5 days): End of Study or Early Termination 
1. Perform physical examination, including weight, and vital signs (blood pressure and pulse 
rate) (Section 8.6.4 ) 
2. Concomitant medications (Section 8.6.18)  
3. Collect blood and urine for la boratory assessments (Section 8.6.6 ) 
4. Perform urine pregnancy test for all wo men of childbearing potential (Section 8.6.7 ) 
5. Perform IGA (Section 8.6.8)  
6. Perform CEA (Section 8.6.9 ) 
7. Perform lesion count (Section 8.6.10 ) 
8. Perform RosaQoL (Section 8.6.11 ) 
9. Perform DLQI (Section  8.6.12 ) 
10. Perform photography of the face on subjects at selected sites (Sections 8.6.15)  
11. Collect study medication, record study medi cation accountability, and assess compliance 
(Sections 8.6.15  and 8.6.19 ) 
12. Assess AEs (Section 8.6.17 ) 
13. Collect diary card (Section 8.6.16 ) 		


	
[CONTACT_23015]â€™s /Journey Medical Page 38 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 14. Complete eCRFs (Section 11.2.1 ) 
8.7.[ADDRESS_122510], the Investigator may perform safety and certain efficacy assessments by [CONTACT_630] (see below). The Investigator may use the technology platform that is currently 
available to them. Suggested platforms include Apple FaceTime, Zoom for Healthcare, 
Facebook Messenger video chat, Microsoft Team, Google Hangouts video, Skype, or any other platform, which is suitable from a tec hnology and data protection perspective, as 
determined by [CONTACT_779].   
o Screening, Baseline and Week  16/ End of Study/ Early Termination visits must be 
conducted in-person. The efficacy asse ssments of Total Inflammatory Lesion 
count, IGA grading, and CEA grading as well as the Quality of Life assessment of DLQI scoring at Baseline and Weeks [ADDRESS_122511] be performed in-person, as 
these serve as input data for the prima ry analysis of the primary and secondary 
endpoints of the study 
o Visits at Week 2, 4, 8 and 12 may be conducted in-person or as virtual (using 
suitable technology platform). QoL assessment of RosaQoL scoring at all visits (including Week 16) and the efficacy assessments of Total Inflammatory Lesion 
count, IGA grading, CEA grading, as well as the QoL assessment of DLQI scoring 
at weeks 2, 4, 8 and 12 may be performed in person or virtually. 
x Source documentation should note that the visi t was performed virtually (not face-to-
face).  If certain study procedures or assessments cannot be completed per the schedule of events, the reason for the missed assessment mu st be noted in the source documentation 
(e.g., COVID-19), captured in the protocol de viations documentation, and reported to the 
IRB/Ethics Committee, as applicable. 
A detailed assessment of COVID-19 related risk and mitigation measures will be documented in 
the appropriate study plans.  		


	
[CONTACT_23015]â€™s /Journey Medical Page 39 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 8.8 Efficacy Assessments 
8.8.1 Co-Primary Efficacy Endpoints  
x Proportion of subjects with IGA (modified sca le without erythema) â€œtreatment successâ€ â€“  
Grade [ADDRESS_122512] a 2-grade reduc tion from Baseline to Week 16, in the 
DFD-29 group compared to placebo. 
x Total inflammatory lesion count (sum of papules, pustules, and nodules) reduction from 
Baseline to Week 16, in the DFD-29 group compared to placebo . 
8.8.2 Secondary Efficacy Endpoints 
x Percentage Change in Total inflammatory les ion count (sum of papules, pustules, and 
nodules) from Baseline to Week 16, in the DFD-[ADDRESS_122513] Placebo and Doxycycline 
capsules 40 mg:  
x Proportion of subjects with IGA treatment success from Baseline to Weeks 2, 4, 8, and 12. 
x Total inflammatory lesion count (sum of papules, pustules, and nodules) reduction from 
Baseline to Weeks 2, 4, 8, and 12. 
x Percentage Change in Total inflammatory les ion count (sum of papules, pustules, and 
nodules) from Baseline to Weeks 2, 4, 8, 12 (a nd 16, in case of DFD-29 vs Doxycycline 
capsules 40 mg comparison).  
x Proportion of subjects with at least a 2-grad e reduction in IGA score from Baseline to 
Weeks 2, 4, 8, 12 and 16. 
x Change in RosaQoL score from Base line to Weeks 2, 4, 8, 12 and 16. 
x Change in DLQI score from Baseline to Weeks 2, 4, 8, 12  (and 16, in case of DFD-29 vs 
Doxycycline capsules 40 mg comparison). 
x Proportion of subjects with at lea st a 2-grade improvement in the CEA score at Weeks 2, 
4, 8, 12 (and 16, in case of DFD-29 vs Doxycycline capsules 40 mg comparison). 
8.[ADDRESS_122514] been defined as parameters regarding safety and tolerability: 		


	
[CONTACT_23015]â€™s /Journey Medical Page 40 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 x Change from Baseline for vi tal signs and clinical laboratory tests. The clinical laboratory 
tests obtained at screening visit will be defined as baseline assessments.   
x Treatment-emergent AEs. 
x Treatment-emergent AEs leading to premature discontinuation of study medication. 
x Treatment-emergent SAEs. 
8.9.2 Definitions of Terms 
[IP_ADDRESS]  Adverse Event 
An AE is defined as any untoward medical occurr ence associated with the use of a drug in humans, 
whether or not considered drug-related (21 Code  of Federal Regulations [CFR] 312.32 (a)). An 
AE can therefore be any unfavorable and uninte nded sign (including an abnormal laboratory 
finding, for example), symptom, or disease temporally  associated with the use of a drug, without 
any judgment about causality. 
A treatment-emergent AE (TEAE)  is any AE temporally associated  with the use of a study drug, 
whether or not considered related to the study drug. 
AEs will be collected by [CONTACT_110187] m subjects, either verbal or recorded in the 
subjectâ€™s diary, by [CONTACT_110188], and by [CONTACT_110189]. All AEs from the time of 
signing of the ICF up to the EOS visit will be recorded. 
Adverse events include: 
x Exacerbation of a pre-existing disease. 
x Increase in frequency or intensity of a pre-e xisting epi[INVESTIGATOR_110150]. 
x Disease or medical condition detected or dia gnosed after study drug administration even 
though it may have been present prior to the start of the study. 
x Continuous persistent disease or symptoms pre sent at Baseline that worsen following the 
start of the study. 
x Events considered by [CONTACT_110190]-mandated procedures. 
x Abnormal assessments, e.g., vital signs or physical  examination findings, must be reported 
as AEs if they represent a clinically significa nt finding that was not present at Baseline or 
worsened during the course of the study. 
x Laboratory test abnormalities must be reported  as AEs if they represent a clinically 
significant finding, symptomatic or not, which was not present at Baseline or worsened 
during the course of the study or led to dose reduction, interruption or permanent 
discontinuation of study drug. 
Adverse events do not include: 
x Medical or surgical procedure, e.g., surgery, endoscopy, tooth extraction, transfusion. 
However, the event leading to the procedure is an  AE. If this event is serious, the procedure 
must be described in the SAE narrative. 
x Pre-existing disease or medical condition that does not worsen. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 41 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122515] from the study  or the use of further treatment for rosacea. 
[IP_ADDRESS]  Suspected Adverse Reaction 
A suspected adverse reaction (SAR) is defined as any AE for which there is reasonable possibility 
that the drug caused the AE (21 CFR 312.32 (a)). 
[IP_ADDRESS]  Unexpected Adverse Event 
An AE or SAR is considered unexpected if it is not listed in the Investigator Brochure or is not 
listed at the specificity or seve rity that has been observed or, if an Investigator Brochure is not 
required or available, is not consistent with the risk information described elsewhere (for example, 
approved prescribing information) (21 CFR 312.32 (a)). 
[IP_ADDRESS]  Serious Adverse Event 
An SAE is defined as any AE or SAR that, in th e view of the investigator or sponsor, results in 
any of the following outcomes (21 CFR 312.32 (a)): 
x Death 
x Life-threatening AE (Note: the term â€œlife -threateningâ€ as used here refers to an event that 
in the view of the investigator or sponsor places  the subject at immediate risk of death at 
the time of the event; it does not include an AE or SAE that, had it occurred in a more 
severe form, might have cau sed death [21 CFR 312.32(a)]) 
x Inpatient hospi[INVESTIGATOR_25411] 
x Persistent or significant incapacity or substa ntial disruption of the ability to conduct normal 
life functions 
x Congenital anomaly/birth defect 
x Any â€œotherâ€ important medical event.  Important medical events that may not result in 
death, be life-threatening, or require hospi[INVESTIGATOR_110151], based 
upon appropriate medical judgment, they may jeopardize the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
The following are not considered an SAE: 
x Treatment on an emergency or outpatient basis fo r an event not fulfilling the definition of 
seriousness given above and not  resulting in hospi[INVESTIGATOR_059]. 
x The following reasons for hospi[INVESTIGATOR_110152], and therefore not SAEs:  
o Hospi[INVESTIGATOR_110153] s urgery, social and/or convenience reasons. 
o Standard monitoring of a pre-existing disease or medical condition that did not 
worsen, e.g., hospi[INVESTIGATOR_110154] a subject with stable 
angina pectoris. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 42 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 o Elective treatment of a pre-existing dise ase or medical condition that did not 
worsen, e.g., hospi[INVESTIGATOR_110155], elective hip replacement 
for arthritis 
[IP_ADDRESS]  Planned Hospi[INVESTIGATOR_059] 
A hospi[INVESTIGATOR_110156] a therapeutic 
intervention and not the result of a new SAE a nd should be recorded as medical history. If the 
planned hospi[INVESTIGATOR_110157] d, the record in the subjectâ€™s medical history 
is considered complete. However, if the event/ condition worsens during the study, it must be 
reported as an AE. 
[IP_ADDRESS]  Pregnancy 
Pregnancies occurring after the first dose of study medication require immediate reporting and 
discontinuation of the study medication. They mu st be reported within [ADDRESS_122516]. Reddyâ€™s Laboratories Ltd, Clinical 
Pharmacovigilance, the Sponsor medical monitor, and the CRO medical monitor within [ADDRESS_122517]. Reddyâ€™s Laboratories Ltd, 
Clinical Pharmacovigilance, the Sponsor medical monitor, and the CRO medical monitor. Upon 
awareness of the outcome of the pregnancy, the PI [INVESTIGATOR_110158] a follow-up Pregnancy Report with any relevant information to [CONTACT_23015]â€™s Laboratories Ltd, Clinical 
Pharmacovigilance, the Sponsor medical monitor, and the CRO medical monitor.  
If the outcome of the pregnancy meets the criteri a for immediate classification of an SAE (e.g., 
spontaneous abortion, stillbirth, neonatal death, or c ongenital anomaly), the investigator will report 
the event by [CONTACT_110191] a completed SAE report form to [CONTACT_23015]â€™s Laboratories Ltd, Clinical 
Pharmacovigilance, the Sponsor medical monitor, a nd the CRO medical monitor within 24 hours 
of being notified of the pregnancy report. 
Details of the pregnancy, delivery a nd health of the infant should be recorded on the Pregnancy 
Report Form. 
The following outcomes of pregnancy fall under the cr iteria for serious adverse events and should 
be reported as such: delivery complications prolonging hospi[INVESTIGATOR_059], spontaneous abortion, stillbirth, death of newborn baby, congenital anom aly, and anomaly in a miscarried/stillborn fetus 
8.9.[ADDRESS_122518] will be  followed for safety monitoring until discharged 
from the study. Follow-up procedures related to pregnancy or AEs or SAEs may continue beyond 
the end of the study. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 43 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 Subjects will be questioned and/or examined by [CONTACT_1720] a qualified designee for 
occurrence of AEs throughout the study. The presenc e or absence of specific AEs should not be 
elicited from subjects. Subjects having AEs will  be monitored with relevant clinical assessments 
and laboratory tests, as deter mined by [CONTACT_093]. 
AEs, actions taken as a result of AEs, and follow-up  results must be recorded in the eCRF, as well 
as in the subjectâ€™s source docum entation. Follow-up laboratory results should be filed with the 
subjectâ€™s source documentation.  
For all AEs that require the subject to be discontinued from the study and SAEs, relevant clinical 
assessments and laboratory tests w ill be repeated as clinically a ppropriate until final resolution or 
stabilization of the event(s). 
All laboratory assessments will be performed centr ally at a certified laboratory selected by [CONTACT_103]. The clinical laboratory values will be reported to the investigator by [CONTACT_110192].  
8.9.4 Assessment of Adverse Events 
[IP_ADDRESS]  Assessment of Severity 
Severity of AEs will be graded according to the following definitions: Mild: Event may be noticeable to subject; does not influence daily activities; usually does not 
require intervention. 
Moderate: Event may make subject uncomfortab le; performance of daily activities may be 
influenced; intervention may be needed. 
Severe: Event may cause noticeable discomfort; usua lly interferes with daily activities; subject 
may not be able to continue in the study; treatment or intervention is usually needed.   
[IP_ADDRESS]  Assessment of Causality 
AEs should be assessed by [CONTACT_110193] a reasonable possibility of 
causal relationship to the study drug and reported as either definite, probable, possible, not related, 
as defined below: 
x Not Related: The event is clearly due to ex traneous causes (e.g., diseases, environment, 
etc.) or the event is most probably produced by [CONTACT_110194]â€™s clinical 
state, therapeutic interventions, or concom itant therapy and does not follow a known 
response pattern to the study product. 
x Possibly Related: The event is temporally related  to study product use but can be explained 
by [CONTACT_11693]. Information on the effect of study product withdrawal may be lacking. 
x Probably Related: The event is temporally relat ed to study product use and is consistent 
with known effects of the study product and/or improves upon withdrawal of the study 
product.  
x Definitely Related: The event follows a reasona ble temporal sequence from the time of 
study product administration and/or follows a known response pattern to the study product 
and could not have been produced by [CONTACT_110195]Â´s clinical state, 
therapeutic intervention, or c oncomitant therapy, and either occurs immediately following 		


	
[CONTACT_23015]â€™s /Journey Medical Page 44 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122519] recen t Investigatorâ€™s Brochure . 
[IP_ADDRESS]  Known Potential Toxicities of Investigational Product 
Refer to the Investigator's Brochure OR packag e insert for additional information on AEs related 
to toxicities observed to date. 
8.9.[ADDRESS_122520]. Reddyâ€™s Laboratories Ltd, Clinical 
Pharmacovigilance, the Sponsor medical monitor, and the CRO medical monitor within 24 hours of the investigator's knowledge of the event. 
All SAEs must be recorded on SAE forms, irresp ective of the study drug received by [CONTACT_423], 
whether or not this event is considered by [CONTACT_7185]. 
These SAE forms must be sent via E- mail to [CONTACT_23015]â€™s Laboratori es Ltd, Clinical 
Pharmacovigilance, the Sponsor medical monitor, and the CRO medical monitor. The investigator 
must assess the relationship to study drug. 
All AEs, regardless of the relationship to study drug, will be recorded in the subject source record 
and eCRF.  Standard medical ter minology should be used when describing AEs. . The anatomical 
location of the AEs must be specified where applicable. 
Whenever possible a diagnosis should be made and recorded on the eCRF rather than listing signs 
and symptoms. Intermittent AEs can be recorded once 
The following information should be recorded on the eCRF: 
x Description 
x Onset date 
x Resolution date or date of death 
x Severity of the event (see Intensity for details) 
x Study drug use continued or not 
x Outcome of the event (resolved, unknown, death) 
x Relationship to study drug (see Relations hip to Study drug (Causality) for details) 
x Indication of whether the event is serious (see Seriousness for details) 
x Actions taken including treatment with concomitant medication 
When reporting an SAE, the Investigator/designee must complete the SAE reporting form and 
mention Investigatorâ€™s name/designeeâ€™s name, email ID, the telephone number where they can be 
reached, and the protocol number and title as we ll as the information in the above paragraph. 
Contact [CONTACT_110196]: 		


	
[CONTACT_23015]â€™s /Journey Medical Page 45 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122521]. Reddyâ€™s Laboratories Ltd, Pharmacovigilance:  
Pharmacovigilance GPVC Email:  [EMAIL_2175]. 
 
[CONTACT_23015]â€™s Laboratories Ltd, Medic al Monitor: 
Srinivas Shenoy B., MD Director, Clinical Development 
Cell number: +91-[PHONE_2522] 
E-mail:  [EMAIL_2176] 
 
Symbio (CRO) Medical Monitor: Evyan Cord-Cruz, MD  Director, Medical Affairs Tel No: [PHONE_2523] (cell)/ [PHONE_2524] (direct) E-mail: [EMAIL_2177] 
In addition, the Sponsor (or Sponsorâ€™s designated ag ent) will evaluate the expectedness according 
to the reference document/the IB.  
An adverse event or suspected adverse reaction is c onsidered â€œunexpectedâ€ if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed in the SAE.  
Serious adverse event reporting will extend from  signing of informed consent until End of Study 
Visit /Early Termination visit.  
An SAE which occurs before administration of study drug (e.g. during screening/as a result of 
screening) will not be considered for expedited reporting to the FDA but will be entered in the 
subjectâ€™s source records and the eCRF  
If the subject took one or more suspect medicinal product(s) other than the study drug, the relevant 
manufacturer(s) of this medicinal product(s), will  be informed about the SAE by [CONTACT_456]. 
Preliminary reports will be followed by [CONTACT_110197][INVESTIGATOR_110159], autopsy reports, hospi[INVESTIGATOR_110160]. Follow-up information about a prev iously reported SAE must also be reported 
within 24 hours of receiving it. The Sponsorâ€™s Ph armacovigilance depart ment may contact [CONTACT_110198].  
Suspected (considered related to the study drug) a nd Unexpected (not previously described in the 
reference safety document), Serious Adverse Reactions (S[LOCATION_003]Rs) will be expedited by [CONTACT_103]â€™s Pharmacovigilance department to Heal th Authorities. The CRO will report to the 
EC/IRBs as applicable. All SAEs judged to be  S[LOCATION_003]Rs and reportable will be unblinded. S[LOCATION_003]R 		


	
[CONTACT_23015]â€™s /Journey Medical Page 46 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 related unblinding will be performed by [CONTACT_37922]â€™s Pharmacovigilance department as outlined 
within the Safety Management Plan.  
The Sponsor must notify FDA of any SAE observe d during conduct of the study, which is serious 
and unexpected and for which there is a reasonable possibility that it has caused the SAE, for which 
there is basis to believe there is a causal re lationship between the drug a nd the occurrence of the 
adverse event (21 CFR 312.32(c)(1)(i)), as soon as possible but in no case later than 15 calendar 
days after becoming aware of its occurrence as per regulatory guidelines. (21 CFR 320.31(d)(3)).  
If the AE is fatal or life-threatening, and with reas onable possibility of its being related to the study 
drug, the Sponsor must also notify the FDA as soon as possible but in no case later than 7 calendar 
days after becoming aware of its occurrence as per regulatory guidelines (21 CFR 320.31(d)(3)). 
Unblinding Instructions: 
Breaking the blind The blind should ordinarily be broken for all SAE IND safety report submitted to FDA. 
The unblinding procedures and follow-up will be pe rformed in accordance with the protocol and 
the Sponsorâ€™s SOPs.  
All SAEs observed in the investigational drug group, if considered drug related (Suspected 
Adverse Reaction) will be reported to the FDA as an unblinded IND Safety Report 
If the blind is broken and a subject with an adve rse event was receiving placebo, the event should 
not be reported in an IND safety report because there is not a reasonable possibility that the drug 
caused the adverse event. 
The blind should not be broken at the study site level except in a medical emergency (where 
knowledge of the study drug received would affect the treatment of the emergency) or regulatory 
requirement (e.g., for SAEs or death).  
For medical emergency, the blind must only be  broken following discussion on a case-by-case 
basis, at the discretion of the Investigator/treating physician/sponsor. 
If the blind is broken, the date, time, and reason m ust be recorded in the subjectâ€™s source record, 
eCRF, and any associated AE report.  
If an Investigator, site personnel performing asse ssments, or subject, is unblinded, the unblinding 
incident and unblinded subject must be listed as a major protocol deviation. 
A subject for whom the blind is broken will di scontinue study product and be scheduled for a 
safety follow up visit and then discontinued from th e study. The subject will be encouraged to stay 
in the study until the AE is resolved or stabilized. 
For regulatory requirement, reporting of SAEs not previously unblinded at the site level, the blind 
will be broken by [CONTACT_110199].  
All other individuals, including primary investigators , will receive notification of the SAE in the 
form of a blinded report unless the SAE was previously  unblinded at the site level due to a medical 
emergency. 
Laboratory and Vital Signs Variables Vital signs and laboratory abnormalities should be reported  as an AE if they are considered to be 
clinically significant, as per Investigatorâ€™s judgmen t. If an abnormal laborat ory value is associated 		


	
[CONTACT_23015]â€™s /Journey Medical Page 47 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 with clinical signs and symptoms, the sign/symptom should be reported as an AE and the 
associated abnormal laboratory result s hould be considered additional information. 
Subjects who have had an SAE must be followed clinically until the event has resolved, become 
clinically insignificant, has stabilized, or the subj ect is lost to follow-up. The investigator must 
provide a written follow-up report as soon as possi ble when any additional information is received. 
New SAEs occurring at any time after the 30-d ay follow-up period after study drug discontinuation 
(whichever comes first) may be reported to [CONTACT_23015]â€™s Laboratories Ltd, Clinical 
Pharmacovigilance within 24 hours of the investig ator's knowledge of the event, if felt appropriate 
by [CONTACT_473]. 
Such information will only be entered into the drug safety database and hence will not affect study 
closure. 
8.9.7 Discontinuation, Treatment Interruption,  and Unblinding of Blinded Treatment 
Due to Safety Observations 
[IP_ADDRESS]  Discontinuation 
See Section 8.3.[ADDRESS_122522] is discontinued early from 
the study, the activities specified for Vi sit 7 on the Study Flow Chart (Section 3.2) should be 
completed if possible. 
[IP_ADDRESS]  Treatment Interruption 
A subject may have the study medication temporarily interrupted for any of the following reasons: 
x An AE 
x A diagnostic or therapeutic procedure 
x An abnormal assessment (e.g., vital signs or laboratory abnormalities) 
x Administrative reasons, in particular withd rawal of the subjectâ€™s consent, or subject 
becomes uncooperative. 
The reason for study drug interruption or premature  discontinuation must be documented in the 
eCRF and the Sponsor must be informed. If the reason for discontinuation from study drug is an 
abnormal result on a laboratory test or vital sign this information will be recorded as an AE in the 
eCRF. The subject will remain under the supervision of the investigator until satisfactory health 
has returned.  
[IP_ADDRESS]  Modification of Dose of Study Medication 
The dose of study medication to any subject may not be modified. If necessary, a subject must be 
discontinued for the reasons described in Section 8.3.3 .  
[IP_ADDRESS]  Unblinding Treatment for a Subject During the Study 
IWRS will be used for emergency unblinding. The identity of the study drug may be revealed only 
if the subject experiences a medical eme rgency whose management would benefit by [CONTACT_110200]. Subjects who have been unblinded by [CONTACT_110201]. 
The occurrence of any unblinding during the study must be clearly justified and explained by [CONTACT_1275]. Before unblinding, every attempt must be made by [CONTACT_110202] 		


	
[CONTACT_23015]â€™s /Journey Medical Page 48 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122523] be informed 
as soon as possible before or after the code break. 
8.10 Criteria for Early Termination of the Study 
There are no prespecified criteria for terminating the study early.  
Further recruitment in the study or at (a) particular site(s) may be stopped due to insufficient 
compliance with the protocol, GCP, and/or ot her applicable regulatory requirements, procedure-
related problems, or the number of discontinuations  for administrative reasons is too high.  
9 STATISTICAL METHODS 
Prior to the database lock, a detailed, finalized Statis tical Analysis Plan (SAP) will be completed 
and placed on file. The Statistical Analysis Plan will contain a more comprehensive explanation 
than that provided here of the methodology used in the statistical analyses, as well as the rules and 
data handling conventions used to  perform the analyses and th e procedure used to account for 
missing data. In case of any conflicting /discrep ant information pertaining to statistical analysis 
between the methodology specified hereunder and in  the final SAP, the information in the final 
SAP will supersede the protocol. 
9.1 Statistical Analysis Plan 
A statistical analysis plan (SAP) will be writ ten and finalized before the study closure, i.e., 
database closure and unblinding of the randomizati on code of the study. The SAP will provide full 
details of the analyses, level of significance to be us ed, the data displays and the algorithms to be 
used for data derivations.  
9.2 Analysis Populations 
Three populations are defined for the analyses: 
x Intent-to-treat (ITT) population: This analysis population includes all randomized subjects 
(i.e., assigned to a treatment group). The IT T population will be the primary population for 
the efficacy analysis. 
x Safety population: This analysis population includes subjects who received at least one 
dose of study medication and had at least one sa fety assessment post-Baseline. The safety 
population will be used for analysis of tolerability and safety variables.  
x Per-protocol population (PP): This analysis population comprises all subjects who did not 
violate the protocol in a way that might affe ct the evaluation of the effect of the study 
medication on the primary endpoint (without major protocol violations or deviations). Key 
protocol deviation categories that would influenc e the decision to include a subject in the 
PP population at time of final review before study database lock will be pre-specified in 
the Statistical Analysis Plan (SAP).   
9.3 General Considerations 
9.3.1 Handling of Missing Data 
All safety analyses will be performed on data available at the time point considered. In summary 
tables, the number of subjects with missing data will be presented unless otherwise specified. In 
calculation of percentages, subjects with missing da ta will not be considered in the numerator or 
denominator unless otherwise specified. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 49 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 For the ITT analysis of the total inflammatory lesion count, IGA, CEA, and DLQI efficacy data, 
in case of missing measurements at Week 16, mult iple imputation (MI) will be used to impute the 
missing values. 
9.4 Demographics, Medical History, Baseline Characteristics, and Concomitant 
Medications 
The statistical significance of any treatment group difference in the distribution of categorical 
variables such as gender w ill be tested using Cochran â€“Mantel â€“Haenszel (CMH) test for general 
association adjusted for site. Continuous variables, such as age, will be analyzed using a 2-way 
analysis of variance (ANOVA) model with site and treatment as a fixed effect. 
Summary statistics (mean, median, standard  deviation, min, max, number of available 
observations) will be provided for continuous dem ographic variables (e.g., age, height, weight). 
Individual subject listings of demographic data will be provided. 
Qualitative demographic characteristics (gende r, race) will be summarized by [CONTACT_110203]. Medical history will be summarized  by [CONTACT_9313] (SOC) and preferred term 
(PT). Other Baseline subject ch aracteristics (e.g., physical examination clinical findings, and 
inclusion/exclusion checklist) will only be listed.  
Distributions of these parameters will be compared between the treatment groups only 
descriptively. No statistical i nference will be performed. 
9.[ADDRESS_122524] Doxycycline capsu les 40 mg for multiple primary and secondary 
endpoints will be addressed through a fixed-seque nce method described in the SAP, according to 
a defined sequence for the primary and secondary endpoints.  
9.6.1 Co-Primary Endpoints 
x The proportion of subjects with IGA treatment success (DFD-29 versus placebo) will be 
investigated with a CMH test f or general association adjusted  for site. Treatment success 
is defined as having at least a 2-grade reduct ion from Baseline with Grade 0 or 1 at Week 
16. 
x The difference between the trea tments (DFD-29 versus placebo) in terms of the change 
from Baseline in the total inflammatory lesi on count at Week 16 will be tested using an 
Analysis of Covariance (ANCOVA) model with treatment and site included in the model 
as fixed effects, and Baseline total i nflammatory lesion count as a covariate. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 50 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 9.6.2 Secondary Endpoints 
x Percentage Change in Total inflammatory les ion count (sum of papules, pustules, and 
nodules) from Baseline to Week 16, in the DF D-29 group compared to Placebo will be 
tested using an ANCOVA model with treatmen t and site included as fixed effects, and 
Baseline total inflammatory les ion count as a covariate. 
x Proportion of subjects with IGA treatment succ ess (DFD-29 versus Doxycycline capsules 
40 mg) at Week [ADDRESS_122525] for general association adjusted 
for site.  
x The difference between treatments (DFD- 29 versus Doxycycline capsules 40 mg) in 
change from Baseline in the total inflammatory lesion count at Week [ADDRESS_122526] a 2-grade reduction in CEA score from Baseline to 
Week 16 will be investigated with a CMH tes t for general association adjusted for site 
(DFD-29 versus placebo).  
x Change in DLQI score from Baseline to Week  16 will be investigated using an ANCOVA 
model with treatment and site included in the model as fixed effects,  and Baseline DLQI 
as a covariate (DFD-29 versus placebo). 
9.6.[ADDRESS_122527] recen t Medical Dictionary for Regulatory Activities 
(MedDRA) version 24.1. 
All AEs and SAEs are coded using the most recent MedDRA version 24.1. 
The treatment-emergent AEs are tabulated by [CONTACT_72064] (SOC), and individual preferred 
terms within each SOC by [CONTACT_1570]. The number and percentage of subjects who 
experienced AEs coded with the same preferred te rm and SOC will be summarized by [CONTACT_6490] (in descending order according to the incidence in the investigational study drug group). 
AEs will also be tabulated by [CONTACT_110204]. Summary tables will be 
accompanied by [CONTACT_110205], including pre-dose events.  
SAEs, AEs leading to premature discontinuation of study drug, and AEs of special interest each 
will be listed and summarized similarly to AEs. 
Reasons for death will only be listed. 
Reasons for premature discontinuation of study drug will be listed and summarized by [CONTACT_110206]. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 51 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122528] units. 
Concomitant medications will be  classified according to the W orld Health Organization (WHO) 
Drug Dictionary and will be pre sented in data listings. 
9.[ADDRESS_122529] a 2-grade reduction from Baseline with Grade 0 or 1. 
x The difference between treatments in terms of the change from Baseline in the total 
inflammatory lesion count at Weeks 2, 4, 8, a nd 12 will be tested using mixed model 
repeated measures (MMRM) with treatment, si te, visit, and treatment-by-visit interaction 
included in the model as fixed effects, Ba seline total inflammatory lesion count as a 
covariate, and the subjects as a random factor. 
x Percentage Change in Total inflammatory lesi on count from Baseline to Weeks 2, 4, 8, 12 
(and 16, in case of DFD-29 vs Doxycycline capsules 40 mg comparison) will be tested using MMRM with treatment, site, visit, and treatment-by-visit interaction included in the 
model as fixed effects, Baseline total infl ammatory lesion count as a covariate, and the 
subjects as a random factor 
x The proportion of subjects with at least a 2-grade  reduction in IGA score from Baseline to 
Weeks 2, 4, 8, 12, and [ADDRESS_122530] for general association 
adjusted for site. 
x Change in total RosaQoL sc ore from Baseline to Week s 2, 4, 8, 12 and 16 will be 
investigated using MMRM with treatment, site , visit, and treatment-by-visit interaction 
included in the model as fixed effects, Baseli ne RosaQoL as a covariate, and the subjects 
as a random factor. 
x Change in DLQI score from Baseline to Weeks 2, 4, 8, 12 (and 16, in case of DFD-29 vs 
Doxycycline capsules 40 mg comparison) w ill be investigated using MMRM with 
treatment, site, visit, and treatment-by-visit  interaction included in the model as fixed 
effects, Baseline DLQI as a covariate,  and the subjects as a random factor. 
x Proportion of subjects with at lea st a 2-grade improvement in the CEA score at Weeks 2, 
4, 8, 12 (and 16, in case of DFD-29 vs Doxycyc line capsules 40 mg comparison) will be 
investigated with a CMH test for general association adjusted for site. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 52 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 Exploratory analyses for the following subgroups will be performed for the primary endpoints: 
x Males versus females 
x Baseline rosacea severity: moderate (IGA 3) versus severe (IGA 4) 
x Baseline total inflammatory lesion count  below versus above the median count 
x Fitzpatrick skin types I-III versus IV-VI 
9.9 Sample Size Determination 
The sample size for this study was calculated on th e basis of the results obtained from the preceding 
Phase 2 study with orally administered DFD-29 (4 0 mg) in the treatment of inflammatory lesions 
of papulopustular rosacea. 
Assuming a difference in treatment means of 8.[ADDRESS_122531] deviation of 16.3 for the e ndpoint of inflammatory lesion count reduction, 
the sample size required is calculated to be 100 DFD-29 s ubjects and 65 placebo subjects to 
achieve 90% power, with a two-sided alpha of 0.05, for a 3:2 randomization ratio. 
Assuming the proportion of IGA treatment success w ill be 0.60 in the DFD-29 group and 0.15 in 
the placebo group, the sample size of 100 DFD-29  subjects and 65 placeb o subjects will provide 
greater than 99% power to detect a statistically significant difference in these proportion at 
alpha=0.05 (two-sided), for a 3:[ADDRESS_122532] de viation of 16.3 for the endpoint of inflammatory 
lesion count reduction, the sample s ize required is calculated to be  101 subjects in each treatment 
group to achieve 90% power, with a two-sided al pha of 0.05. In addition, the sample size of 
100 subjects per group will yield greater than 90% power to detect a difference in the assumed 
proportion of IGA success of 0.60 in the DFD-29 group 0.35 in the Doxycycline capsules 40 mg group, using a two-sided alpha of 0.05.  
Based on these sample size calculations and an as sumed dropout rate of 20%, the final sample size 
will be [ADDRESS_122533] both plac ebo and Doxycycline capsules 40 mg in terms 
of efficacy on both co-primary endpoints. 
Efforts will be made to minimize the dropout ra te and to ensure proper follow-up of subjects. 
10 ETHICS 
10.1 Informed Consent 
The principles of informed consent, according to  FDA regulations and International Council for 
Harmonization (ICH) guidelines on GCP, will be  followed. A copy of th e proposed ICF must be 
submitted with the protocol to the IRB for approval. 
The informed consent process must be conducted and the ICF must be signed before each subject 
undergoes any Visit [ADDRESS_122534]â€™s signed ICF must be 
kept on file by [CONTACT_110207]. A copy of the 		


	
[CONTACT_23015]â€™s /Journey Medical Page 53 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122535]â€™s medical record 
indicating the date informed consent was obtained. 
10.[ADDRESS_122536] (IRB) 
The study protocol and ICF must be approved in writing by [CONTACT_1629] a ppropriate IRB as defined by [CONTACT_110208]. 
Any changes to the protocol or a change of i nvestigator approved by [CONTACT_110209]â€™s I RB and documentation of that approval provided to the sponsor or designee. 
Records of the IRB review and approval of all docu ments pertaining to this study must be kept on 
file by [CONTACT_110210]. SAEs must also be reported to the IRB. 
Periodic status reports must be submitted to the IRB  at least annually, as well as notification of 
completion of the study and a final report  at study completion or termination.  
The investigator will ensure that an IRB that complies with the requirements set forth in [ADDRESS_122537] initials. 
However, in compliance with federal guideline s regarding the monitoring of clinical studies and 
in fulfillment of his/her obligations to the sponsor,  the investigator must permit the study monitor, 
sponsor representative or auditor, and/or FDA representative or other regulatory authority to 
review the portion of the subjectâ€™s medical record that is directly related to the study.  This shall 
include all study-relevant documentation includi ng medical history to verify eligibility, 
admission/discharge summaries for hospi[INVESTIGATOR_7959] o ccurring while the subject is enrolled in the 
study, and autopsy reports if a death occurs during the study. 
As part of the required content of  informed consent, each subject must be informed that his or her 
medical chart may be reviewed by [CONTACT_456], the s ponsorâ€™s authorized representatives, FDA  or 
other regulatory authority. If access to the medical record requires a separate waiver or authorization, it is the investigatorâ€™s re sponsibility to obtain such permission from the subject in 
writing before the subject is entered into the study. 
10.4 Study Registration 
The study will be registered by [CONTACT_110211].gov, which is a service of th e [LOCATION_002] National Institutes of Health. 
11 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] 
11.1 Site Regulatory Documents Required for Initiation 
The sponsor or designee will receive the following documents prior to the initiation of the study: 
x Completed, signed Form FDA 1572 
x Current curricula vitae, signed and dated, for the principal investigator (PI) and 
co-investigators named on Form FDA 1572 
x Current license(s) of the PI [INVESTIGATOR_6254]-investigators named on Form FDA 1572 
x Documentation of IRB approval of the study protocol, investigator, and ICF 		


	
[CONTACT_23015]â€™s /Journey Medical Page 54 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122538] notifying the sponsor. 
11.2.1  Electronic Case  Report Forms (eCRFs)  
Database set-up will be performed by [CONTACT_110212] ( CRO) in collaboration with the electronic data 
capture (EDC) vendor, using an  appropriate fully validated, [ADDRESS_122539] will be recorded by [CONTACT_110213]. Only 
authorized site personnel will be able to enter/modify/correct data to the eCRF. 
Approved staff at CRO will verify  all data entered into eCRFs for completeness and accuracy with 
reference to the source documents and records and will issue manual data queries to correct 
missing data or discrepancies found agains t the source within the EDC system. 
Data validation will consist of automated and manua l edit checks that are created directly into 
EDC. Automated edit checks will be executed on  all data points defined and documented by [CONTACT_110214]. Study metrics will be reported from the EDC system. 
After all data have been verif ied by [CONTACT_110215], an Investigator or Sub-Investigator 
(listed on Form FDA 1572) is required to review and approve all eCRFs prior to database lock and 
breaking of the blind.  
After database lock, each  site will be provided with a transportable media that will include the 
eCRF data from their site for local archival purposes. 
Quality assurance verification via a 10% database audit of eCRF data will  be conducted before the 
treatment assignment codes are released. 
eCRF entry must be kept current to reflec t the subjectâ€™s status during the study.  Subjects are not 
to be identified on eCRFs by [CONTACT_2300]; appropriately coded identif ication must be used. The 
investigator must keep a separate log of the subjectsâ€™ names and addresses.  		


	
[CONTACT_23015]â€™s /Journey Medical Page 55 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122540] â€™s eCRF. eCRFs, source documents, and copi[INVESTIGATOR_110161]. The following should also be available for review: 
x Subject Screening Log, which should reflect th e reason any subject screened for the study 
was found to be ineligible 
x Delegation of Authority Log, which will list al l site personnel with their responsibilities as 
delegated by [CONTACT_978] [INVESTIGATOR_110162]. This  log will be maintained at the site throughout 
the study 
x Monitoring Log, which will list the date and purpose of all monitoring visits by [CONTACT_110216] 
x Enrollment Log, which will list subject init ials and start and end dates for all enrolled 
subjects 
x Drug Inventory/Packing Slip, which will list  the total amount of drug shipped to the site 
and received and signed for by [CONTACT_093] 
x Study Medication Dispensing Log, which will  list the total amount  of study medication 
dispensed to and returned by [CONTACT_6992] 
x ICF which must be available for each subjec t and be verified for proper documentation 
x All correspondence 
11.2.[ADDRESS_122541]â€™s medical notes.  These documents, which are considered â€œsource data ,â€ should include 
documentation of: 
x Demographic information 
x Evidence supporting the diagnosis/condition for which the subject is being studied 
x General information supporting the subjectâ€™s participation in the study  
x General history and physical findings 
x Hospi[INVESTIGATOR_94585] (if applicable) 
x Each study visit by [CONTACT_568], including any relev ant findings/notes by [CONTACT_093](s), 
occurrence (or lack) of AEs, and changes in medication usage, including the date the study 
medication was started and stopped 
x Any additional visits during the study 
x Any relevant telephone conversations with the subject regarding the study or possible AEs 
x An original, signed ICF for study participation 		


	
[CONTACT_23015]â€™s /Journey Medical Page 56 of 64 
DFD-29-CD-004 Version: 2.[ADDRESS_122542]- specific printouts/reports of tests and procedures 
performed as a requirement of the study. During m onitoring visits the monitor will validate eCRF 
entries against these sources of data. 
11.3 Study Monitoring 
Symbio (CRO) will be responsible for monit oring the study according to GCP and applicable 
regulations. The study will be monitored by a Cl inical Research Associate (CRA) in compliance 
with GCP, ICH guidelines, and applicable regulati ons. The investigator will be visited by a CRA 
prior to the study and at regular  intervals during the course of the st udy. These visits are to verify 
adherence to the protocol. The CRA will review the ICFs and verify eCRF entries by [CONTACT_110217] (hospi[INVESTIGATOR_307]/clinic/office records) that will be made available for this 
purpose. The CRA will review the mainten ance of regulatory documentation and drug 
accountability (to the bottle level). The monitor will review the progress of the study with the 
investigator and other site personnel on a regular basis. At the end of the study, a closeout 
monitoring visit will be performed. Monitoring vi sits will be arranged with site personnel in 
advance at a mutually acceptable time. Sufficient time must be allowed by [CONTACT_110218]. The coordinator and/or investigator 
should be available to answer questions or reso lve data clarifications. Adequate time and space for 
these visits should be made availab le by [CONTACT_110219].  
11.4 Audits and Inspections 
During the course of the study and/or after it has been completed, 1 or more sites may be audited 
by [CONTACT_110220]. The purpo se of the audit is to  determine whether or 
not the study is being conducted and monitore d in compliance with recognized GCP/ICH 
guidelines and regulations. 
Additionally, the study may be inspected by [CONTACT_110221]. These inspections may take 
place at any time during or after completion of  the study and are based on local regulations. 
11.5 Modifications to the Protocol 
The procedures defined in the protoc ol and eCRFs will be carefully reviewed to ensure that all 
parties involved with the study fully understand the prot ocol. To ensure the validity of the data, no 
deviations from the protocol (with minimal exce ptions) may be made unless the issue is broad 
enough to warrant revision of the protocol. Such revisions must be submitted to and have 
documented approval from the sponsor and IRB pr ior to implementation. The only circumstance 
in which an amendment may be initiated without prior IRB approval is to eliminate an apparent 
immediate hazard to a subject or subjects. In su ch a case, however, the investigator must notify 
the sponsor immediately and the IRB within [ADDRESS_122543] eCRFs and all other relevant data and records to CRO. The 
investigator will complete and report (submis sion of eCRFs) his/her study in satisfactory 
compliance with the protocol as soon as possible after the completion of the study. 
The investigator must submit a final report to the IRB and the sponsor within 1 month of study 
completion or early termination. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 57 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 12 CONFIDENTIALITY, USE OF INFORMATION, AND PUBLICATION 
All information related to this study that is s upplied by [CONTACT_110222]. This inf ormation includes but is not limited to data, 
materials (protocol, eCRFs), equipment, expe rience (whether of a scientific, technical, 
engineering, operational, or commercial nature), designs, specifications, know-how, product uses, 
processes, formulae, costs, financial data, marketi ng plans and direct sell ing systems, customer 
lists, and technical and commercial information re lating to customers or business projections used 
by [CONTACT_68612]. Any data, inventi ons, or discoveries collected or developed as a 
result of this study are considered confidential.  This confidential informati on shall remain the sole 
property of the sponsor, shall not be disclose d to any unauthorized person or used in any 
unauthorized manner without written  consent of the sponsor, and shall not be used except in the 
performance of the study. 
The information developed during the course of this st udy is also considered  confidential and will 
be used by [CONTACT_110223]. The information may be 
disclosed as deemed necessary by [CONTACT_456]. To  allow the use of the information derived from 
this study, the investigator is obliged to provide  the sponsor with complete test results and all data 
developed in the study. The information obtained duri ng this study may be made available to other 
investigators who are conducting similar studies. 
The investigator shall not make any publication related to this study without the express written 
permission of the sponsor. If the investigator wants to publish or present the results of this study, 
he or she agrees to provide the sponsor with an  abstract, manuscript, and/or presentation for review 
[ADDRESS_122544] to suggested publication/presentation and/or its timing (at 
the sponsorâ€™s sole discretion).  
[ADDRESS_122545] 
classification. Acta Derm Venereol. 2010; 90:269 â€“73. 
2. Berg M, LidÃ©n S. An epi[INVESTIGATOR_110163]. Acta Derm Venereol. 1989;69(5):419 â€423. 
3. Bewley A, Fowler J, SchÃ¶fer H, Kerrouche N, Ri ves V. Erythema of Rosacea Impairs Health-Related 
Quality of Life: Results of a Meta-a nalysis. Dermatol Ther (Heidelb). 2016 Mar 16. [Epub ahead of print] 
4. Dean OM, Maes M, Ashton M, Berk L, Kanchanataw an B, Sughondhabirom A, Tangwongchai S, Ng C, 
Dowling N, Malhi GS, Berk M. Protocol and ration ale-the efficacy of mino cycline as an adjunctive 
treatment for major depressive disorder: a double b lind, randomised, placebo controlled trial. Clin 
Psychopharmacol Neurosci. 2014;12(3):180-8. 
5. Del Rosso JQ. Oral Doxycyclin e in the Management of Acne Vulgar is: Current Perspectives on Clinical 
Use and Recent Findings with a New Double-scored  Small Tablet Formulation. J Clin Aesthet Dermatol. 
2015;8(5):19-26. 
6. Dosal JR, Rodriguez GL, Pezon CF, Li H, Keri JE. Effect of tetracyclines on the development of vascular 
disease in veterans with acne or rosacea: a retrospective coho rt study. J Invest Dermatol. 
2014;134(8):2267-9. 
7. Duman N, Ersoy Evans S, Atakan N. Rosacea and cardio vascular risk factors: a case control study. J Eur 
Acad Dermatol Venereol. 2014;28(9):1165-9. 
8. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clus tering of autoimmune diseases in patients with 
rosacea. J Am Acad Dermatol. 2016a;74(4):667-672.e1. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 58 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 9. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with Rosacea Ha ve Increased Risk of 
Depression and Anxiety Disorders:  A Danish Nationwide Cohort Study. Dermatology. 2016b;232(2):208-
13. 
10. Feldman SR, Huang WW, Huynh TT. Current drug th erapi[INVESTIGATOR_110164]: a chronic vascular and 
inflammatory skin diseas e. J Manag Care Spec Pharm. 2014;20(6):623-9. 
11. Garrido-Mesa N, Zarzuelo A, GÃ¡lvez J. Mino cycline: far beyond an antibiotic. Br J Pharmacol. 
2013;169(2):337-52. 
12. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a p leitropic family of compounds with 
promising therapeutic properties. Review of the literat ure. Am J Physiol Cell Physiol. 2010;299(3):C539-
48. 
13. Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity  of rosacea and depression: an analysis of the 
National Ambulatory Medical Care  Survey and National Hospi[INVESTIGATOR_110165]--Outpatient 
Department data collected by [CONTACT_941] U.S.  National Center for Health S tatistics from 1995 to 2002. Br J 
Dermatol. 2005;153(6):1176-81.  
14. Holmes AD, Steinhoff M. Integrativ e concepts of rosacea pathoph ysiology, clinical presentation, and 
new therapeutics. Exp Dermatol. 2016 Jul 4. doi:10.1111/exd.[ZIP_CODE]. [Epub ahead of print] 
15. Hua TC, Chung PI, Chen YJ, Wu LC, Chen YD, Hwang CY, Chu SY, Chen CC, Lee DD, Chang YT, Liu 
HN. Cardiovascular comorbidities in p atients with rosacea: A nationwide case-control study from Taiwan. 
J Am Acad Dermatol. 2015;73(2):249-54. 
16. Jackson JM, Kircik LH, Lorenz DJ. Efficacy of extended-release 45 mg oral minocycline and extended-
release 45 mg oral minocycline plus 15%  azelaic acid in the treatment of acne rosacea. J Drugs Dermatol. 
2013;12(3):292-8. 
17. Scheinfeld N, Berk T. A review of the diagnosis and treatment of rosacea. Postgrad Med. 2010;122(1):139 â€
143. doi:10.3810/pgm.2010.01.2107 
18. Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epi[INVESTIGATOR_110166] U.K. Br J 
Dermatol. 2012 Sep;167(3):598-605. 
19. Spoendlin J, Voegel JJ, Jick SS, Meier CR. Migraine,  triptans, and the risk of developi[INVESTIGATOR_110167]: a 
population-based study within the [LOCATION_008] . J Am Acad Dermatol. 2013;69(3):399-406. 
20. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, Mess C, Cevikbas F, Rivier M, 
Carlavan I, DÃ©ret S, Rosignoli C, Metze D, Luger TA, Voegel JJ. Clinical, cellu lar, and molecular aspects 
in the pathophysiology of rosacea. J Invest ig Dermatol Symp Proc. 2011;15(1):2-11. 
21. Tan J, SchÃ¶fer H, Araviiskaia E, Audibert F, Kerr ouche N, Berg M; RISE study group. Prevalence of 
rosacea in the general population of [LOCATION_013] and Russ ia -The RISE study. J Eur Acad Dermatol Venereol. 
2016 Mar;30(3):428-34.  
22. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. In terventions for rosacea. 
Cochrane Database Syst  Rev. 2015;(4):CD003262. 
23. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis  S. Systematic review of rosacea treatments. J Am 
Acad Dermatol. 2007;56(1): 107â€115. doi:10.1016/j.jaad.2006.04.084  
24. Vemuri RC, Gundamaraju R, Sekaran SD, Manikam R. Major pathophysiological correlations of rosacea: a 
complete clinical appraisal.  Int J Med Sci. 2015;12(5):387-96. 
25. Wilkin J, Dahl M, Detmar M, Drak e L, Feinstein A, Odom R, Powell F.  Standard classification of rosacea: 
Report of the National Rosacea Society Expert Comm ittee on the Classification and Staging of Rosacea. J 
Am Acad Dermatol. 2002;46(4):584-7. 
26. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F; National Rosacea Society Expert 
Committee. Standard grading system fo r rosacea: report of the Nation al Rosacea Society Expert Committee 
on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907-12. 		


	
[CONTACT_23015]â€™s /Journey Medical Page 59 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 27. Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime Rep. 
2014;6:50. 
28. Oracea capsules [package insert]. Fort Worth, TX: Galderma Labor atories, L.P.; 2013.OR Doxycycline 40 
mg capsules [package insert].  D ailyMed - DOXYCYCLINE capsule (nih.gov) 
 		


	
[CONTACT_23015]â€™s /Journey Medical Page 60 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022  
Protocol Template  Confidential MW501.T01 Version 2019OCT11 14 INVESTIGATOR AGREEMENT 
Protocol Number:  DFD-29-CD-004 
Protocol Title:  A Multicenter, Randomized, Double-B lind, Parallel-Group, Active and 
Placebo-Controlled Study to Asse ss the Safety, Efficacy, and 
Tolerability of Oral DFD-[ADDRESS_122546] (HIPAA), and local 
regulatory guidelines. I will attempt to complete the study within the time designated. I will ensure that the rights, safety, and welfare of subjects unde r my care are protected. I will ensure control of 
the drugs under investigation in this study. I will provide copi[INVESTIGATOR_68541]-
related information supplied by [CONTACT_110224]. I will discuss this information with them  to assure that they  are adequately informed 
regarding the drug and conduct of th e study. I agree to keep records on all subject information 
(case report forms, shipment and drug return for ms, and all other information collected during the 
study) and drug disposition in accordance with FDA regulations. I will not enroll any subjects into 
this protocol until IRB approval and sponsor approval are obtained. 
           
Investigator Name (Print)   
 
            
Investigator Signature      [CONTACT_1782] 		


	
[CONTACT_23015]â€™s /Journey Medical Page 61 of 64 
DFD-29-CD-004 Version: 2.0 
MVOR-1 23 June 2022 
 
Protocol Template  Confidential MW501.T01 Version 2019OCT11 15 APPENDICES 
15.1 IGA Scale 
 
 
 
15.2 CEA Scale 
 
Score Definition 
0 = None  No redness present  
1 = Mild  Slight pi[INVESTIGATOR_96225]  
2 = Moderate  Definite redness  
3 = Significant Marked erythema 
4 = Severe  Fiery redness  
 
Tan J, Liu H, Leyden JJ, Leoni MJ. Reliability of clinician er ythema assessment grading scale. J Am Acad Dermatol. 
2014;71(4):760-3. 
 
  Score Definition  
0 = Clear No signs or symptoms present 
1 = Near clear Rare papules 
2 = Mild Some papules and pustules with no plaques 
3 = Moderate Several small/large papules and pustules, 
with no plaques 
4 = Severe Numerous small/large papules and pustules, 
with or without plaques and nodules 		


	
[CONTACT_23015]â€™s /Journey Medical Page 62 of 64 
DFD-29-CD-004 Version: 2.0 
 MVOR-1 23 June 2022 
 
Protocol Template  Confidential MW501.T01 Version 2019OCT11 15.3 Diagram of the Face 
 
 
Each pustule to be marked by â€œXâ€ at its approximate location. 
Each papule to be marked by â€œâ–¡â€ at its approximate location. 
Each nodule/cyst to be marked by â€œOâ€ at its approximate location 
  
		


	
[CONTACT_23015]â€™s /Journey Medical Page 63 of 64 
DFD-29-CD-004 Version: 2.0 
 MVOR-1 23 June 2022 
 
Protocol Template  Confidential MW501.T01 Version 2019OCT11 15.4 Example of the Rosacea Quality of Life Instrument 
 
		


	
[CONTACT_23015]â€™s /Journey Medical Page 64 of 64 
DFD-29-CD-004 Version: 2.0 
 MVOR-1 23 June 2022 
 
Protocol Template  Confidential MW501.T01 Version 2019OCT11 15.5 Example of the Dermatology Life Quality Index 
 
 
		


	